-
1
-
-
75149163334
-
Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression
-
[PMID: 19861128]
-
Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 513-521, 521.e1-6 [PMID: 19861128 DOI: 10.1053/j.gastro.2009.09.067]
-
(2010)
Gastroenterology
, vol.138
-
-
Davis, G.L.1
Alter, M.J.2
El-Serag, H.3
Poynard, T.4
Jennings, L.W.5
-
2
-
-
84902136664
-
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm
-
[PMID: 24713005]
-
Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, Vogel W, Mendes Correa MC, Hézode C, Lázaro P, Akarca U, Aleman S, Balik I, Berg T, Bihl F, Bilodeau M, Blasco AJ, Brandão Mello CE, Bruggmann P, Buti M, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HS, Cramp ME, Dore GJ, Doss W, Duberg AS, El-Sayed MH, Ergör G, Esmat G, Falconer K, Félix J, Ferraz ML, Ferreira PR, Frankova S, García-Samaniego J, Gerstoft J, Giria JA, Gonçales FL, Gower E, Gschwantler M, Guimarães Pessôa M, Hindman SJ, Hofer H, Husa P, Kåberg M, Kaita KD, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Marinho RT, Marotta P, Mauss S, Moreno C, Murphy K, Negro F, Nemecek V, Örmeci N, Øvrehus AL, Parkes J, Pasini K, Peltekian KM, Ramji A, Reis N, Roberts SK, Rosenberg WM, Roudot-Thoraval F, Ryder SD, Sarmento-Castro R, Semela D, Sherman M, Shiha GE, Sievert W, Sperl J, Stärkel P, Stauber RE, Thompson AJ, Urbanek P, Van Damme P, van Thiel I, Van Vlierberghe H, Vandijck D, Wedemeyer H, Weis N, Wiegand J, Yosry A, Zekry A, Cornberg M, Müllhaupt B, Estes C. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat 2014; 21 Suppl 1: 34-59 [PMID: 24713005 DOI: 10.1111/jvh.12248]
-
(2014)
J Viral Hepat
, vol.21
, pp. 34-59
-
-
Razavi, H.1
Waked, I.2
Sarrazin, C.3
Myers, R.P.4
Idilman, R.5
Calinas, F.6
Vogel, W.7
Mendes Correa, M.C.8
Hézode, C.9
Lázaro, P.10
Akarca, U.11
Aleman, S.12
Balik, I.13
Berg, T.14
Bihl, F.15
Bilodeau, M.16
Blasco, A.J.17
Brandão Mello, C.E.18
Bruggmann, P.19
Buti, M.20
Calleja, J.L.21
Cheinquer, H.22
Christensen, P.B.23
Clausen, M.24
Coelho, H.S.25
Cramp, M.E.26
Dore, G.J.27
Doss, W.28
Duberg, A.S.29
El-Sayed, M.H.30
Ergör, G.31
Esmat, G.32
Falconer, K.33
Félix, J.34
Ferraz, M.L.35
Ferreira, P.R.36
Frankova, S.37
García-Samaniego, J.38
Gerstoft, J.39
Giria, J.A.40
Gonçales, F.L.41
Gower, E.42
Gschwantler, M.43
Guimarães Pessôa, M.44
Hindman, S.J.45
Hofer, H.46
Husa, P.47
Kåberg, M.48
Kaita, K.D.49
Kautz, A.50
Kaymakoglu, S.51
Krajden, M.52
Krarup, H.53
Laleman, W.54
Lavanchy, D.55
Marinho, R.T.56
Marotta, P.57
Mauss, S.58
Moreno, C.59
Murphy, K.60
Negro, F.61
Nemecek, V.62
Örmeci, N.63
Øvrehus, A.L.64
Parkes, J.65
Pasini, K.66
Peltekian, K.M.67
Ramji, A.68
Reis, N.69
Roberts, S.K.70
Rosenberg, W.M.71
Roudot-Thoraval, F.72
Ryder, S.D.73
Sarmento-Castro, R.74
Semela, D.75
Sherman, M.76
Shiha, G.E.77
Sievert, W.78
Sperl, J.79
Stärkel, P.80
Stauber, R.E.81
Thompson, A.J.82
Urbanek, P.83
Van Damme, P.84
van Thiel, I.85
Van Vlierberghe, H.86
Vandijck, D.87
Wedemeyer, H.88
Weis, N.89
Wiegand, J.90
Yosry, A.91
Zekry, A.92
Cornberg, M.93
Müllhaupt, B.94
Estes, C.95
more..
-
3
-
-
33748114343
-
The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide
-
[PMID: 16879891]
-
Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-538 [PMID: 16879891 DOI: 10.1016/j.jhep.2006.05.013]
-
(2006)
J Hepatol
, vol.45
, pp. 529-538
-
-
Perz, J.F.1
Armstrong, G.L.2
Farrington, L.A.3
Hutin, Y.J.4
Bell, B.P.5
-
4
-
-
84866898184
-
Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a communitybased long-term prospective study
-
[PMID: 22811301]
-
Lee MH, Yang HI, Lu SN, Jen CL, You SL, Wang LY, Wang CH, Chen WJ, Chen CJ. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a communitybased long-term prospective study. J Infect Dis 2012; 206: 469-477 [PMID: 22811301 DOI: 10.1093/infdis/jis385]
-
(2012)
J Infect Dis
, vol.206
, pp. 469-477
-
-
Lee, M.H.1
Yang, H.I.2
Lu, S.N.3
Jen, C.L.4
You, S.L.5
Wang, L.Y.6
Wang, C.H.7
Chen, W.J.8
Chen, C.J.9
-
5
-
-
84957729536
-
Type II Mixed Cryoglobulinemia in patients with Hepatitis C Virus: treatment with Pegylated-interferon and ribavirin
-
Malaguarnera M, Scuderi L, Ardiri Al, Malaguarnera G, Bertino N, Ruggeri IM, Carmela Greco G, Ozyalcn E, Bertino E, Bertino G. Type II Mixed Cryoglobulinemia in patients with Hepatitis C Virus: treatment with Pegylated-interferon and ribavirin. Acta Medica Mediterr 2015; 31: 431
-
(2015)
Acta Medica Mediterr
, vol.31
, pp. 431
-
-
Malaguarnera, M.1
Scuderi, L.2
Ardiri, A.L.3
Malaguarnera, G.4
Bertino, N.5
Ruggeri, I.M.6
Carmela Greco, G.7
Ozyalcn, E.8
Bertino, E.9
Bertino, G.10
-
6
-
-
84871487025
-
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis
-
[PMID: 23268517]
-
van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Heathcote EJ, Manns MP, Kuske L, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-2593 [PMID: 23268517 DOI: 10.1001/jama.2012.144878]
-
(2012)
JAMA
, vol.308
, pp. 2584-2593
-
-
van der Meer, A.J.1
Veldt, B.J.2
Feld, J.J.3
Wedemeyer, H.4
Dufour, J.F.5
Lammert, F.6
Duarte-Rojo, A.7
Heathcote, E.J.8
Manns, M.P.9
Kuske, L.10
Zeuzem, S.11
Hofmann, W.P.12
de Knegt, R.J.13
Hansen, B.E.14
Janssen, H.L.15
-
7
-
-
84891364951
-
Causes of death and characteristics of decedents with viral hepatitis, United States, 2010
-
[PMID: 24065331]
-
Ly KN, Xing J, Klevens RM, Jiles RB, Holmberg SD. Causes of death and characteristics of decedents with viral hepatitis, United States, 2010. Clin Infect Dis 2014; 58: 40-49 [PMID: 24065331 DOI: 10.1093/cid/cit642]
-
(2014)
Clin Infect Dis
, vol.58
, pp. 40-49
-
-
Ly, K.N.1
Xing, J.2
Klevens, R.M.3
Jiles, R.B.4
Holmberg, S.D.5
-
8
-
-
84954448786
-
O86 European responses in focus: comparing viral hepatitis and hiv related deaths in europe 1990-2010 in the global burden of disease study 2010
-
Cowie BC, Allard N, MacLachlan JH. O86 European responses in focus: comparing viral hepatitis and hiv related deaths in europe 1990-2010 in the global burden of disease study 2010. J Hepatol 2014; 60 (1 Supplement): 35-36 [DOI: 10.1016/S0168-8278(14)60088-XS]
-
(2014)
J Hepatol
, vol.60
, Issue.1
, pp. 35-36
-
-
Cowie, B.C.1
Allard, N.2
MacLachlan, J.H.3
-
9
-
-
84897465495
-
Mortality among persons in care with hepatitis C virus infection: the Chronic Hepatitis Cohort Study (CHeCS), 2006-2010
-
[PMID: 24523214]
-
Mahajan R, Xing J, Liu SJ, Ly KN, Moorman AC, Rupp L, Xu F, Holmberg SD. Mortality among persons in care with hepatitis C virus infection: the Chronic Hepatitis Cohort Study (CHeCS), 2006-2010. Clin Infect Dis 2014; 58: 1055-1061 [PMID: 24523214 DOI: 10.1093/cid/ciu077]
-
(2014)
Clin Infect Dis
, vol.58
, pp. 1055-1061
-
-
Mahajan, R.1
Xing, J.2
Liu, S.J.3
Ly, K.N.4
Moorman, A.C.5
Rupp, L.6
Xu, F.7
Holmberg, S.D.8
-
10
-
-
84896492970
-
Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients
-
[PMID: 24122848]
-
Hsu YC, Lin JT, Ho HJ, Kao YH, Huang YT, Hsiao NW, Wu MS, Liu YY, Wu CY. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology 2014; 59: 1293-1302 [PMID: 24122848 DOI: 10.1002/hep.26892]
-
(2014)
Hepatology
, vol.59
, pp. 1293-1302
-
-
Hsu, Y.C.1
Lin, J.T.2
Ho, H.J.3
Kao, Y.H.4
Huang, Y.T.5
Hsiao, N.W.6
Wu, M.S.7
Liu, Y.Y.8
Wu, C.Y.9
-
11
-
-
84880296165
-
Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan
-
[PMID: 23802888]
-
Hsu CS, Kao JH, Chao YC, Lin HH, Fan YC, Huang CJ, Tsai PS. Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan. Aliment Pharmacol Ther 2013; 38: 415-423 [PMID: 23802888 DOI: 10.1111/apt.12391]
-
(2013)
Aliment Pharmacol Ther
, vol.38
, pp. 415-423
-
-
Hsu, C.S.1
Kao, J.H.2
Chao, Y.C.3
Lin, H.H.4
Fan, Y.C.5
Huang, C.J.6
Tsai, P.S.7
-
12
-
-
84936061716
-
Potential contributions of the tobacco nicotine-derived nitrosamine ketone (NNK) in the pathogenesis of steatohepatitis in a chronic plus binge rat model of alcoholic liver disease
-
[PMID: 25618784]
-
Zabala V, Tong M, Yu R, Ramirez T, Yalcin EB, Balbo S, Silbermann E, Deochand C, Nunez K, Hecht S, de la Monte SM. Potential contributions of the tobacco nicotine-derived nitrosamine ketone (NNK) in the pathogenesis of steatohepatitis in a chronic plus binge rat model of alcoholic liver disease. Alcohol Alcohol 2015;50: 118-131 [PMID: 25618784 DOI: 10.1093/alcalc/agu083]
-
(2015)
Alcohol Alcohol
, vol.50
, pp. 118-131
-
-
Zabala, V.1
Tong, M.2
Yu, R.3
Ramirez, T.4
Yalcin, E.B.5
Balbo, S.6
Silbermann, E.7
Deochand, C.8
Nunez, K.9
Hecht, S.10
de la Monte, S.M.11
-
13
-
-
79955623053
-
Circulating endothelial-coagulative activation markers after smoking cessation: a 12-month observational study
-
[PMID: 21198559]
-
Caponnetto P, Russo C, Di Maria A, Morjaria JB, Barton S, Guarino F, Basile E, Proiti M, Bertino G, Cacciola RR, Polosa R. Circulating endothelial-coagulative activation markers after smoking cessation: a 12-month observational study. Eur J Clin Invest 2011; 41: 616-626 [PMID: 21198559 DOI: 10.1111/j.1365-2362.2010.02449.x]
-
(2011)
Eur J Clin Invest
, vol.41
, pp. 616-626
-
-
Caponnetto, P.1
Russo, C.2
Di Maria, A.3
Morjaria, J.B.4
Barton, S.5
Guarino, F.6
Basile, E.7
Proiti, M.8
Bertino, G.9
Cacciola, R.R.10
Polosa, R.11
-
14
-
-
33846567157
-
Obesity and related diseases: an epidemiologic study in eastern Sicily
-
[PMID: 17108868]
-
Bertino G, Ardiri AM, Alì FT, Boemi PM, Cilio D, Di Prima P, Fisichella A, Ierna D, Neri S, Pulvirenti D, Urso G, Mauceri B, Valenti M, Bruno CM. Obesity and related diseases: an epidemiologic study in eastern Sicily. Minerva Gastroenterol Dietol 2006;52: 379-385 [PMID: 17108868]
-
(2006)
Minerva Gastroenterol Dietol
, vol.52
, pp. 379-385
-
-
Bertino, G.1
Ardiri, A.M.2
Alì, F.T.3
Boemi, P.M.4
Cilio, D.5
Di Prima, P.6
Fisichella, A.7
Ierna, D.8
Neri, S.9
Pulvirenti, D.10
Urso, G.11
Mauceri, B.12
Valenti, M.13
Bruno, C.M.14
-
15
-
-
84913592791
-
Natural history of hepatitis C
-
[PMID: 25443346]
-
Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol 2014; 61: S58-S68 [PMID: 25443346 DOI: 10.1016/j.jhep.2014.07.012]
-
(2014)
J Hepatol
, vol.61
, pp. S58-S68
-
-
Westbrook, R.H.1
Dusheiko, G.2
-
16
-
-
84885796029
-
Systemic therapies in hepatocellular carcinoma: present and future
-
[PMID: 24106903]
-
Bertino G, Di Carlo I, Ardiri A, Calvagno GS, Demma S, Malaguarnera G, Bertino N, Malaguarnera M, Toro A, Malaguarnera M. Systemic therapies in hepatocellular carcinoma: present and future. Future Oncol 2013; 9: 1533-1548 [PMID: 24106903 DOI: 10.2217/fon.13.171]
-
(2013)
Future Oncol
, vol.9
, pp. 1533-1548
-
-
Bertino, G.1
Di Carlo, I.2
Ardiri, A.3
Calvagno, G.S.4
Demma, S.5
Malaguarnera, G.6
Bertino, N.7
Malaguarnera, M.8
Toro, A.9
Malaguarnera, M.10
-
17
-
-
84903835849
-
Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies
-
[PMID: 25089265]
-
Bertino G, Demma S, Ardiri A, Proiti M, Gruttadauria S, Toro A, Malaguarnera G, Bertino N, Malaguarnera M, Malaguarnera M, Di Carlo I. Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies. Biomed Res Int 2014; 2014: 203693 [PMID: 25089265 DOI: 10.1155/2014/203693]
-
(2014)
Biomed Res Int
, vol.2014
, pp. 203693
-
-
Bertino, G.1
Demma, S.2
Ardiri, A.3
Proiti, M.4
Gruttadauria, S.5
Toro, A.6
Malaguarnera, G.7
Bertino, N.8
Malaguarnera, M.9
Malaguarnera, M.10
Di Carlo, I.11
-
18
-
-
84928116687
-
The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies
-
[PMID: 25893197]
-
Bertino G, Demma S, Ardiri A, Proiti M, Mangia A, Gruttadauria S, Toro A, Di Carlo I, Malaguarnera G, Bertino N, Malaguarnera M, Malaguarnera M. The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies. Biomed Res Int 2015; 2015: 731469 [PMID: 25893197 DOI: 10.1155/2015/731469]
-
(2015)
Biomed Res Int
, vol.2015
, pp. 731469
-
-
Bertino, G.1
Demma, S.2
Ardiri, A.3
Proiti, M.4
Mangia, A.5
Gruttadauria, S.6
Toro, A.7
Di Carlo, I.8
Malaguarnera, G.9
Bertino, N.10
Malaguarnera, M.11
Malaguarnera, M.12
-
19
-
-
84869405641
-
Elevated serum levels of Chromogranin A in hepatocellular carcinoma
-
[PMID: 23173843]
-
Biondi A, Malaguarnera G, Vacante M, Berretta M, D'Agata V, Malaguarnera M, Basile F, Drago F, Bertino G. Elevated serum levels of Chromogranin A in hepatocellular carcinoma. BMC Surg 2012;12 Suppl 1: S7 [PMID: 23173843 DOI: 10.1186/1471-2482-12-S1-S7]
-
(2012)
BMC Surg
, vol.12
, pp. S7
-
-
Biondi, A.1
Malaguarnera, G.2
Vacante, M.3
Berretta, M.4
D'Agata, V.5
Malaguarnera, M.6
Basile, F.7
Drago, F.8
Bertino, G.9
-
20
-
-
84864459298
-
Hepatocellualar carcinoma serum markers
-
[PMID: 22846859]
-
Bertino G, Ardiri A, Malaguarnera M, Malaguarnera G, Bertino N, Calvagno GS. Hepatocellualar carcinoma serum markers. Semin Oncol 2012; 39: 410-433 [PMID: 22846859 DOI: 10.1053/j.semin oncol.2012.05.001]
-
(2012)
Semin Oncol
, vol.39
, pp. 410-433
-
-
Bertino, G.1
Ardiri, A.2
Malaguarnera, M.3
Malaguarnera, G.4
Bertino, N.5
Calvagno, G.S.6
-
21
-
-
84857603190
-
Diagnostic and prognostic value of alpha-fetoprotein, des-γ-carboxy prothrombin and squamous cell carcinoma antigen immunoglobulin M complexes in hepatocellular carcinoma
-
[PMID: 22193346]
-
Bertino G, Neri S, Bruno CM, Ardiri AM, Calvagno GS, Malaguarnera M, Toro A, Malaguarnera M, Clementi S, Bertino N, Di Carlo I. Diagnostic and prognostic value of alpha-fetoprotein, des-γ-carboxy prothrombin and squamous cell carcinoma antigen immunoglobulin M complexes in hepatocellular carcinoma. Minerva Med 2011; 102: 363-371 [PMID: 22193346]
-
(2011)
Minerva Med
, vol.102
, pp. 363-371
-
-
Bertino, G.1
Neri, S.2
Bruno, C.M.3
Ardiri, A.M.4
Calvagno, G.S.5
Malaguarnera, M.6
Toro, A.7
Malaguarnera, M.8
Clementi, S.9
Bertino, N.10
Di Carlo, I.11
-
22
-
-
79952284046
-
Prognostic and diagnostic value of des-γ-carboxy prothrombin in liver cancer
-
[PMID: 21031166]
-
Bertino G, Ardiri AM, Calvagno GS, Bertino N, Boemi PM. Prognostic and diagnostic value of des-γ-carboxy prothrombin in liver cancer. Drug News Perspect 2010; 23: 498-508 [PMID: 21031166 DOI: 10.1358/dnp.2010.23.8]
-
(2010)
Drug News Perspect
, vol.23
, pp. 498-508
-
-
Bertino, G.1
Ardiri, A.M.2
Calvagno, G.S.3
Bertino, N.4
Boemi, P.M.5
-
23
-
-
77952743696
-
In chronic viral hepatitis without malignancy, abnormal serum carbohydrate 19-9 antigen levels are associated with liver disease severity and are related to different viral aetiology
-
[PMID: 19880358]
-
Bertino G, Ardiri AM, Calvagno GS, Boemi PM. In chronic viral hepatitis without malignancy, abnormal serum carbohydrate 19-9 antigen levels are associated with liver disease severity and are related to different viral aetiology. Dig Liver Dis 2010; 42: 458-459 [PMID: 19880358 DOI: 10.1016/j.dld.2009.09.011]
-
(2010)
Dig Liver Dis
, vol.42
, pp. 458-459
-
-
Bertino, G.1
Ardiri, A.M.2
Calvagno, G.S.3
Boemi, P.M.4
-
24
-
-
72949112674
-
Some patients with HCC haven't abnornormal des-gamma-carboxy prothrombin and alpha-fetoprotein levels
-
[PMID: 19776714]
-
Bertino G, Ardiri AM, Santonocito MM, Boemi PM. Some patients with HCC haven't abnornormal des-gamma-carboxy prothrombin and alpha-fetoprotein levels. Panminerva Med 2009; 51: 133-134 [PMID: 19776714]
-
(2009)
Panminerva Med
, vol.51
, pp. 133-134
-
-
Bertino, G.1
Ardiri, A.M.2
Santonocito, M.M.3
Boemi, P.M.4
-
25
-
-
57349187662
-
A study about mechanisms of des-gamma-carboxy prothrombin's production in hepatocellular carcinoma
-
[PMID: 18927526]
-
Bertino G, Ardiri AM, Boemi PM, Ierna D, Interlandi D, Caruso L, Minona E, Trovato MA, Vicari S, Li Destri G, Puleo S. A study about mechanisms of des-gamma-carboxy prothrombin's production in hepatocellular carcinoma. Panminerva Med 2008; 50: 221-226 [PMID: 18927526]
-
(2008)
Panminerva Med
, vol.50
, pp. 221-226
-
-
Bertino, G.1
Ardiri, A.M.2
Boemi, P.M.3
Ierna, D.4
Interlandi, D.5
Caruso, L.6
Minona, E.7
Trovato, M.A.8
Vicari, S.9
Li Destri, G.10
Puleo, S.11
-
26
-
-
84876149257
-
Global epidemiology of hepatitis C virus infection: new estimates of agespecific antibody to HCV seroprevalence
-
[PMID: 23172780]
-
Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of agespecific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-1342 [PMID: 23172780 DOI: 10.1002/hep.26141]
-
(2013)
Hepatology
, vol.57
, pp. 1333-1342
-
-
Mohd Hanafiah, K.1
Groeger, J.2
Flaxman, A.D.3
Wiersma, S.T.4
-
27
-
-
78751621217
-
Evolving epidemiology of hepatitis C virus
-
[PMID: 21091831]
-
Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17: 107-115 [PMID: 21091831 DOI: 10.1111/j.1469-0691.2010.03432.x]
-
(2011)
Clin Microbiol Infect
, vol.17
, pp. 107-115
-
-
Lavanchy, D.1
-
28
-
-
49649118223
-
Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression
-
[PMID: 18563841]
-
Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008; 48: 418-431 [PMID: 18563841 DOI: 10.1002/hep.22375]
-
(2008)
Hepatology
, vol.48
, pp. 418-431
-
-
Thein, H.H.1
Yi, Q.2
Dore, G.J.3
Krahn, M.D.4
-
29
-
-
33947360829
-
Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study
-
[PMID: 17326216]
-
Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegnù L, Mazzella G, Ascione A, Santantonio T, Piccinino F, Andreone P, Mangia A, Gaeta GB, Persico M, Fagiuoli S, Almasio PL. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45: 579-587 [PMID: 17326216 DOI: 10.1002/hep.21492]
-
(2007)
Hepatology
, vol.45
, pp. 579-587
-
-
Bruno, S.1
Stroffolini, T.2
Colombo, M.3
Bollani, S.4
Benvegnù, L.5
Mazzella, G.6
Ascione, A.7
Santantonio, T.8
Piccinino, F.9
Andreone, P.10
Mangia, A.11
Gaeta, G.B.12
Persico, M.13
Fagiuoli, S.14
Almasio, P.L.15
-
30
-
-
1442308277
-
Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well?
-
[PMID: 14996679]
-
Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 2004; 140: 370-381 [PMID: 14996679 DOI: 10.7326/0003-4819-140-8-200404200-00009]
-
(2004)
Ann Intern Med
, vol.140
, pp. 370-381
-
-
Zeuzem, S.1
-
31
-
-
15644380122
-
Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy
-
[PMID: 9382365]
-
Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, Kilani A, Areias J, Auperin A, Benhamou JP, Degott C, Erlinger S. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997; 127: 875-881 [PMID: 9382365 DOI: 10.7326/0003-4819-127-10-199711150-00003]
-
(1997)
Ann Intern Med
, vol.127
, pp. 875-881
-
-
Marcellin, P.1
Boyer, N.2
Gervais, A.3
Martinot, M.4
Pouteau, M.5
Castelnau, C.6
Kilani, A.7
Areias, J.8
Auperin, A.9
Benhamou, J.P.10
Degott, C.11
Erlinger, S.12
-
32
-
-
84884418448
-
Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C
-
[PMID: 23712051]
-
Poynard T, Moussalli J, Munteanu M, Thabut D, Lebray P, Rudler M, Ngo Y, Thibault V, Mkada H, Charlotte F, Bismut FI, Deckmyn O, Benhamou Y, Valantin MA, Ratziu V, Katlama C. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. J Hepatol 2013; 59: 675-683 [PMID: 23712051 DOI: 10.1016/j.jhep.2013.05.015]
-
(2013)
J Hepatol
, vol.59
, pp. 675-683
-
-
Poynard, T.1
Moussalli, J.2
Munteanu, M.3
Thabut, D.4
Lebray, P.5
Rudler, M.6
Ngo, Y.7
Thibault, V.8
Mkada, H.9
Charlotte, F.10
Bismut, F.I.11
Deckmyn, O.12
Benhamou, Y.13
Valantin, M.A.14
Ratziu, V.15
Katlama, C.16
-
33
-
-
51249090533
-
Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C
-
[PMID: 18593587]
-
Maylin S, Martinot-Peignoux M, Moucari R, Boyer N, Ripault MP, Cazals-Hatem D, Giuily N, Castelnau C, Cardoso AC, Asselah T, Féray C, Nicolas-Chanoine MH, Bedossa P, Marcellin P. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 2008; 135: 821-829 [PMID: 18593587 DOI: 10.1053/j.gastro.2008.05.044]
-
(2008)
Gastroenterology
, vol.135
, pp. 821-829
-
-
Maylin, S.1
Martinot-Peignoux, M.2
Moucari, R.3
Boyer, N.4
Ripault, M.P.5
Cazals-Hatem, D.6
Giuily, N.7
Castelnau, C.8
Cardoso, A.C.9
Asselah, T.10
Féray, C.11
Nicolas-Chanoine, M.H.12
Bedossa, P.13
Marcellin, P.14
-
34
-
-
12244249211
-
Long-term liver histology improvement in patients with chronic hepatitis C and sustained response to interferon
-
[PMID: 12614469]
-
Toccaceli F, Laghi V, Capurso L, Koch M, Sereno S, Scuderi M. Long-term liver histology improvement in patients with chronic hepatitis C and sustained response to interferon. J Viral Hepat 2003; 10: 126-133 [PMID: 12614469 DOI: 10.1046/j.1365-2893.2003.00403.x]
-
(2003)
J Viral Hepat
, vol.10
, pp. 126-133
-
-
Toccaceli, F.1
Laghi, V.2
Capurso, L.3
Koch, M.4
Sereno, S.5
Scuderi, M.6
-
35
-
-
0036242165
-
Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C
-
[PMID: 11984517]
-
Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Ling MH, Albrecht J. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-1313 [PMID: 11984517 DOI: 10.1053/gast.2002.33023]
-
(2002)
Gastroenterology
, vol.122
, pp. 1303-1313
-
-
Poynard, T.1
McHutchison, J.2
Manns, M.3
Trepo, C.4
Lindsay, K.5
Goodman, Z.6
Ling, M.H.7
Albrecht, J.8
-
36
-
-
17144455384
-
Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy
-
[PMID: 10744587]
-
Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, Kuroki T, Nishiguchi S, Sata M, Yamada G, Fujiyama S, Yoshida H, Omata M. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132: 517-524 [PMID: 10744587 DOI: 10.7326/0003-4819-132-7-200004040-00036]
-
(2000)
Ann Intern Med
, vol.132
, pp. 517-524
-
-
Shiratori, Y.1
Imazeki, F.2
Moriyama, M.3
Yano, M.4
Arakawa, Y.5
Yokosuka, O.6
Kuroki, T.7
Nishiguchi, S.8
Sata, M.9
Yamada, G.10
Fujiyama, S.11
Yoshida, H.12
Omata, M.13
-
37
-
-
79957497436
-
A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C
-
[PMID: 21397729]
-
Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011; 9: 509-516.e1 [PMID: 21397729 DOI: 10.1016/j.cgh.2011.03.004]
-
(2011)
Clin Gastroenterol Hepatol
, vol.9
, pp. 509-516.e1
-
-
Backus, L.I.1
Boothroyd, D.B.2
Phillips, B.R.3
Belperio, P.4
Halloran, J.5
Mole, L.A.6
-
38
-
-
77952801344
-
Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C
-
[PMID: 20211180]
-
Fontana RJ, Sanyal AJ, Ghany MG, Lee WM, Reid AE, Naishadham D, Everson GT, Kahn JA, Di Bisceglie AM, Szabo G, Morgan TR, Everhart JE. Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C. Gastroenterology 2010; 138: 2321-2331, 2331. e1-2 [PMID: 20211180 DOI: 10.1053/j.gastro.2010.02.058]
-
(2010)
Gastroenterology
, vol.138
-
-
Fontana, R.J.1
Sanyal, A.J.2
Ghany, M.G.3
Lee, W.M.4
Reid, A.E.5
Naishadham, D.6
Everson, G.T.7
Kahn, J.A.8
Di Bisceglie, A.M.9
Szabo, G.10
Morgan, T.R.11
Everhart, J.E.12
-
39
-
-
38449091418
-
Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis
-
[PMID: 18025443]
-
Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, Manns MP, Hansen BE, Schalm SW, Janssen HL. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147: 677-684 [PMID: 18025443 DOI: 10.7326/0003-4819-147-10-200711200-00003]
-
(2007)
Ann Intern Med
, vol.147
, pp. 677-684
-
-
Veldt, B.J.1
Heathcote, E.J.2
Wedemeyer, H.3
Reichen, J.4
Hofmann, W.P.5
Zeuzem, S.6
Manns, M.P.7
Hansen, B.E.8
Schalm, S.W.9
Janssen, H.L.10
-
40
-
-
0033932001
-
Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome
-
[PMID: 10895429]
-
Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000; 20: 17-35 [PMID: 10895429]
-
(2000)
Semin Liver Dis
, vol.20
, pp. 17-35
-
-
Alter, H.J.1
Seeff, L.B.2
-
41
-
-
0036829816
-
Natural history of chronic hepatitis C
-
[PMID: 12407575]
-
Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36: S35-S46 [PMID: 12407575 DOI: 10.1053/jhep.2002.36806]
-
(2002)
Hepatology
, vol.36
, pp. S35-S46
-
-
Seeff, L.B.1
-
42
-
-
79953173221
-
Boceprevir for untreated chronic HCV genotype 1 infection
-
[PMID: 21449783]
-
Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206 [PMID: 21449783 DOI: 10.1056/NEJMoa1010494]
-
(2011)
N Engl J Med
, vol.364
, pp. 1195-1206
-
-
Poordad, F.1
McCone, J.2
Bacon, B.R.3
Bruno, S.4
Manns, M.P.5
Sulkowski, M.S.6
Jacobson, I.M.7
Reddy, K.R.8
Goodman, Z.D.9
Boparai, N.10
DiNubile, M.J.11
Sniukiene, V.12
Brass, C.A.13
Albrecht, J.K.14
Bronowicki, J.P.15
-
43
-
-
79959438789
-
Telaprevir for previously untreated chronic hepatitis C virus infection
-
[PMID: 21696307]
-
Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-2416 [PMID: 21696307 DOI: 10.1056/NEJMoa1012912]
-
(2011)
N Engl J Med
, vol.364
, pp. 2405-2416
-
-
Jacobson, I.M.1
McHutchison, J.G.2
Dusheiko, G.3
Di Bisceglie, A.M.4
Reddy, K.R.5
Bzowej, N.H.6
Marcellin, P.7
Muir, A.J.8
Ferenci, P.9
Flisiak, R.10
George, J.11
Rizzetto, M.12
Shouval, D.13
Sola, R.14
Terg, R.A.15
Yoshida, E.M.16
Adda, N.17
Bengtsson, L.18
Sankoh, A.J.19
Kieffer, T.L.20
George, S.21
Kauffman, R.S.22
Zeuzem, S.23
more..
-
44
-
-
84861183883
-
Ranking predictors of a sustained viral response for patients with chronic hepatitis C treated with pegylated interferon and ribavirin in Scotland
-
[PMID: 22433796]
-
Innes HA, Hutchinson SJ, Allen S, Bhattacharyya D, Bramley P, Carman B, Delahooke TE, Dillon JF, Goldberg DJ, Kennedy N, Mills PR, Morris J, Morris J, Robertson C, Stanley AJ, Hayes P. Ranking predictors of a sustained viral response for patients with chronic hepatitis C treated with pegylated interferon and ribavirin in Scotland. Eur J Gastroenterol Hepatol 2012; 24: 646-655 [PMID: 22433796 DOI: 10.1097/MEG.0b013e32835201a4]
-
(2012)
Eur J Gastroenterol Hepatol
, vol.24
, pp. 646-655
-
-
Innes, H.A.1
Hutchinson, S.J.2
Allen, S.3
Bhattacharyya, D.4
Bramley, P.5
Carman, B.6
Delahooke, T.E.7
Dillon, J.F.8
Goldberg, D.J.9
Kennedy, N.10
Mills, P.R.11
Morris, J.12
Morris, J.13
Robertson, C.14
Stanley, A.J.15
Hayes, P.16
-
45
-
-
84874777079
-
Evaluation of the hepatitis C virus-infected patient: the initial encounter
-
[PMID: 23243172]
-
Bräu N. Evaluation of the hepatitis C virus-infected patient: the initial encounter. Clin Infect Dis 2013; 56: 853-860 [PMID: 23243172 DOI: 10.1093/cid/cis957]
-
(2013)
Clin Infect Dis
, vol.56
, pp. 853-860
-
-
Bräu, N.1
-
46
-
-
85027927076
-
Treatment decisions and contemporary versus pending treatments for hepatitis C
-
[PMID: 24019151]
-
Trembling PM, Tanwar S, Rosenberg WM, Dusheiko GM. Treatment decisions and contemporary versus pending treatments for hepatitis C. Nat Rev Gastroenterol Hepatol 2013; 10: 713-728 [PMID: 24019151 DOI: 10.1038/nrgastro.2013.163]
-
(2013)
Nat Rev Gastroenterol Hepatol
, vol.10
, pp. 713-728
-
-
Trembling, P.M.1
Tanwar, S.2
Rosenberg, W.M.3
Dusheiko, G.M.4
-
47
-
-
84865093812
-
The changing therapeutic landscape for hepatitis C
-
[PMID: 22676877]
-
Dore GJ. The changing therapeutic landscape for hepatitis C. Med J Aust 2012; 196: 629-632 [PMID: 22676877 DOI: 10.5694/mja11.11531]
-
(2012)
Med J Aust
, vol.196
, pp. 629-632
-
-
Dore, G.J.1
-
48
-
-
0034651580
-
Pathogenesis, natural history, treatment, and prevention of hepatitis C
-
[PMID: 10681285]
-
Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000; 132: 296-305 [PMID: 10681285 DOI: 10.7326/0003-4819-132-4-200002150-00008]
-
(2000)
Ann Intern Med
, vol.132
, pp. 296-305
-
-
Liang, T.J.1
Rehermann, B.2
Seeff, L.B.3
Hoofnagle, J.H.4
-
49
-
-
77957673661
-
Epoetin alpha improves the response to antiviral treatment in HCV-related chronic hepatitis
-
[PMID: 20652232]
-
Bertino G, Ardiri A, Boemi PM, Calvagno GS, Ruggeri IM, Speranza A, Santonocito MM, Ierna D, Bruno CM, Valenti M, Boemi R, Naimo S, Neri S. Epoetin alpha improves the response to antiviral treatment in HCV-related chronic hepatitis. Eur J Clin Pharmacol 2010; 66: 1055-1063 [PMID: 20652232 DOI: 10.1007/s00228-010-0868-4]
-
(2010)
Eur J Clin Pharmacol
, vol.66
, pp. 1055-1063
-
-
Bertino, G.1
Ardiri, A.2
Boemi, P.M.3
Calvagno, G.S.4
Ruggeri, I.M.5
Speranza, A.6
Santonocito, M.M.7
Ierna, D.8
Bruno, C.M.9
Valenti, M.10
Boemi, R.11
Naimo, S.12
Neri, S.13
-
50
-
-
77957565232
-
A multidisciplinary therapeutic approach for reducing the risk of psychiatric side effects in patients with chronic hepatitis C treated with pegylated interferon a and ribavirin
-
[PMID: 20838237]
-
Neri S, Bertino G, Petralia A, Giancarlo C, Rizzotto A, Calvagno GS, Mauceri B, Abate G, Boemi P, Di Pino A, Ignaccolo L, Vadalà G, Misseri M, Maiorca D, Mastrosimone G, Judica A, Palermo F. A multidisciplinary therapeutic approach for reducing the risk of psychiatric side effects in patients with chronic hepatitis C treated with pegylated interferon a and ribavirin. J Clin Gastroenterol 2010;44: e210-e217 [PMID: 20838237 DOI: 10.1097/MCG.0b013e3181d88af5]
-
(2010)
J Clin Gastroenterol
, vol.44
, pp. e210-e217
-
-
Neri, S.1
Bertino, G.2
Petralia, A.3
Giancarlo, C.4
Rizzotto, A.5
Calvagno, G.S.6
Mauceri, B.7
Abate, G.8
Boemi, P.9
Di Pino, A.10
Ignaccolo, L.11
Vadalà, G.12
Misseri, M.13
Maiorca, D.14
Mastrosimone, G.15
Judica, A.16
Palermo, F.17
-
51
-
-
33750342122
-
Psychiatric symptoms induced by antiviral therapy in chronic hepatitis C: comparison between interferon-alpha-2a and interferon-alpha-2b
-
[PMID: 17163300]
-
Neri S, Pulvirenti D, Bertino G. Psychiatric symptoms induced by antiviral therapy in chronic hepatitis C: comparison between interferon-alpha-2a and interferon-alpha-2b. Clin Drug Investig 2006;26: 655-662 [PMID: 17163300]
-
(2006)
Clin Drug Investig
, vol.26
, pp. 655-662
-
-
Neri, S.1
Pulvirenti, D.2
Bertino, G.3
-
52
-
-
80053037913
-
The supplementation of acetyl-L-carnitine decreases fatigue and increases quality of life in patients with hepatitis C treated with pegylated interferon-α 2b plus ribavirin
-
[PMID: 21923249]
-
Malaguarnera M, Vacante M, Bertino G, Neri S, Malaguarnera M, Gargante MP, Motta M, Lupo L, Chisari G, Bruno CM, Pennisi G, Bella R. The supplementation of acetyl-L-carnitine decreases fatigue and increases quality of life in patients with hepatitis C treated with pegylated interferon-α 2b plus ribavirin. J Interferon Cytokine Res 2011; 31: 653-659 [PMID: 21923249 DOI: 10.1089/jir.2011.0010]
-
(2011)
J Interferon Cytokine Res
, vol.31
, pp. 653-659
-
-
Malaguarnera, M.1
Vacante, M.2
Bertino, G.3
Neri, S.4
Malaguarnera, M.5
Gargante, M.P.6
Motta, M.7
Lupo, L.8
Chisari, G.9
Bruno, C.M.10
Pennisi, G.11
Bella, R.12
-
53
-
-
81755188299
-
L-carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon-α 2b plus ribavirin
-
[PMID: 22110268]
-
Malaguarnera M, Vacante M, Giordano M, Motta M, Bertino G, Pennisi M, Neri S, Malaguarnera M, Li Volti G, Galvano F. L-carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon-α 2b plus ribavirin. World J Gastroenterol 2011; 17: 4414-4420 [PMID: 22110268]
-
(2011)
World J Gastroenterol
, vol.17
, pp. 4414-4420
-
-
Malaguarnera, M.1
Vacante, M.2
Giordano, M.3
Motta, M.4
Bertino, G.5
Pennisi, M.6
Neri, S.7
Malaguarnera, M.8
Li Volti, G.9
Galvano, F.10
-
54
-
-
84901346067
-
Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α 2b Plus Ribavirin: Effect on Work Performance; A Randomized Clinical Trial
-
[PMID: 24910702]
-
Malaguarnera G, Pennisi M, Gagliano C, Vacante M, Malaguarnera M, Salomone S, Drago F, Bertino G, Caraci F, Nunnari G, Malaguarnera M. Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α 2b Plus Ribavirin: Effect on Work Performance; A Randomized Clinical Trial. Hepat Mon 2014; 14: e11608 [PMID: 24910702 DOI: 10.5812/hepatmon.11608]
-
(2014)
Hepat Mon
, vol.14
-
-
Malaguarnera, G.1
Pennisi, M.2
Gagliano, C.3
Vacante, M.4
Malaguarnera, M.5
Salomone, S.6
Drago, F.7
Bertino, G.8
Caraci, F.9
Nunnari, G.10
Malaguarnera, M.11
-
55
-
-
84877753528
-
Current and future therapies for hepatitis C virus infection
-
[PMID: 23675659]
-
Liang TJ, Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med 2013; 368: 1907-1917 [PMID: 23675659 DOI: 10.1056/NEJMra1213651]
-
(2013)
N Engl J Med
, vol.368
, pp. 1907-1917
-
-
Liang, T.J.1
Ghany, M.G.2
-
56
-
-
55549117151
-
Hepatitis C virus infection protein network
-
[PMID: 18985028]
-
de Chassey B, Navratil V, Tafforeau L, Hiet MS, Aublin-Gex A, Agaugué S, Meiffren G, Pradezynski F, Faria BF, Chantier T, Le Breton M, Pellet J, Davoust N, Mangeot PE, Chaboud A, Penin F, Jacob Y, Vidalain PO, Vidal M, André P, Rabourdin-Combe C, Lotteau V. Hepatitis C virus infection protein network. Mol Syst Biol 2008; 4: 230 [PMID: 18985028 DOI: 10.1038/msb.2008.66]
-
(2008)
Mol Syst Biol
, vol.4
, pp. 230
-
-
de Chassey, B.1
Navratil, V.2
Tafforeau, L.3
Hiet, M.S.4
Aublin-Gex, A.5
Agaugué, S.6
Meiffren, G.7
Pradezynski, F.8
Faria, B.F.9
Chantier, T.10
Le Breton, M.11
Pellet, J.12
Davoust, N.13
Mangeot, P.E.14
Chaboud, A.15
Penin, F.16
Jacob, Y.17
Vidalain, P.O.18
Vidal, M.19
André, P.20
Rabourdin-Combe, C.21
Lotteau, V.22
more..
-
57
-
-
70349513508
-
A genome-wide genetic screen for host factors required for hepatitis C virus propagation
-
[PMID: 19717417]
-
Li Q, Brass AL, Ng A, Hu Z, Xavier RJ, Liang TJ, Elledge SJ. A genome-wide genetic screen for host factors required for hepatitis C virus propagation. Proc Natl Acad Sci USA 2009; 106: 16410-16415 [PMID: 19717417 DOI: 10.1073/pnas.0907439106]
-
(2009)
Proc Natl Acad Sci USA
, vol.106
, pp. 16410-16415
-
-
Li, Q.1
Brass, A.L.2
Ng, A.3
Hu, Z.4
Xavier, R.J.5
Liang, T.J.6
Elledge, S.J.7
-
58
-
-
34547913440
-
Cellular cofactors affecting hepatitis C virus infection and replication
-
[PMID: 17616579]
-
Randall G, Panis M, Cooper JD, Tellinghuisen TL, Sukhodolets KE, Pfeffer S, Landthaler M, Landgraf P, Kan S, Lindenbach BD, Chien M, Weir DB, Russo JJ, Ju J, Brownstein MJ, Sheridan R, Sander C, Zavolan M, Tuschl T, Rice CM. Cellular cofactors affecting hepatitis C virus infection and replication. Proc Natl Acad Sci USA 2007; 104: 12884-12889 [PMID: 17616579 DOI: 10.1073/pnas.0704894104]
-
(2007)
Proc Natl Acad Sci USA
, vol.104
, pp. 12884-12889
-
-
Randall, G.1
Panis, M.2
Cooper, J.D.3
Tellinghuisen, T.L.4
Sukhodolets, K.E.5
Pfeffer, S.6
Landthaler, M.7
Landgraf, P.8
Kan, S.9
Lindenbach, B.D.10
Chien, M.11
Weir, D.B.12
Russo, J.J.13
Ju, J.14
Brownstein, M.J.15
Sheridan, R.16
Sander, C.17
Zavolan, M.18
Tuschl, T.19
Rice, C.M.20
more..
-
59
-
-
61849160363
-
A functional genomic screen identifies cellular cofactors of hepatitis C virus replication
-
[PMID: 19286138]
-
Tai AW, Benita Y, Peng LF, Kim SS, Sakamoto N, Xavier RJ, Chung RT. A functional genomic screen identifies cellular cofactors of hepatitis C virus replication. Cell Host Microbe 2009; 5: 298-307 [PMID: 19286138 DOI: 10.1016/j.chom.2009.02.001]
-
(2009)
Cell Host Microbe
, vol.5
, pp. 298-307
-
-
Tai, A.W.1
Benita, Y.2
Peng, L.F.3
Kim, S.S.4
Sakamoto, N.5
Xavier, R.J.6
Chung, R.T.7
-
60
-
-
84883445154
-
Epidemiology and natural history of HCV infection
-
[PMID: 23817321]
-
Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013; 10: 553-562 [PMID: 23817321 DOI: 10.1038/nrgastro.2013.107]
-
(2013)
Nat Rev Gastroenterol Hepatol
, vol.10
, pp. 553-562
-
-
Hajarizadeh, B.1
Grebely, J.2
Dore, G.J.3
-
61
-
-
34249024924
-
Replication of hepatitis C virus
-
[PMID: 17487147]
-
Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007; 5: 453-463 [PMID: 17487147 DOI: 10.1038/nrmicro1645]
-
(2007)
Nat Rev Microbiol
, vol.5
, pp. 453-463
-
-
Moradpour, D.1
Penin, F.2
Rice, C.M.3
-
62
-
-
84857373372
-
Hepatitis C virus host cell entry
-
[PMID: 22440961]
-
Ploss A, Evans MJ. Hepatitis C virus host cell entry. Curr Opin Virol 2012;2: 14-19 [PMID: 22440961 DOI: 10.1016/j.coviro.2011.12.007]
-
(2012)
Curr Opin Virol
, vol.2
, pp. 14-19
-
-
Ploss, A.1
Evans, M.J.2
-
63
-
-
79952461113
-
Assembly of infectious hepatitis C virus particles
-
[PMID: 21146993]
-
Bartenschlager R, Penin F, Lohmann V, André P. Assembly of infectious hepatitis C virus particles. Trends Microbiol 2011; 19: 95-103 [PMID: 21146993 DOI: 10.1016/j.tim.2010.11.005]
-
(2011)
Trends Microbiol
, vol.19
, pp. 95-103
-
-
Bartenschlager, R.1
Penin, F.2
Lohmann, V.3
André, P.4
-
64
-
-
80053241157
-
Virus-host interactomes and global models of virus-infected cells
-
[PMID: 21855347]
-
Friedel CC, Haas J. Virus-host interactomes and global models of virus-infected cells. Trends Microbiol 2011; 19: 501-508 [PMID: 21855347 DOI: 10.1016/j.tim.2011.07.003]
-
(2011)
Trends Microbiol
, vol.19
, pp. 501-508
-
-
Friedel, C.C.1
Haas, J.2
-
65
-
-
48749104048
-
Innate immune modulation by RNA viruses: emerging insights from functional genomics
-
[PMID: 18654572]
-
Katze MG, Fornek JL, Palermo RE, Walters KA, Korth MJ. Innate immune modulation by RNA viruses: emerging insights from functional genomics. Nat Rev Immunol 2008; 8: 644-654 [PMID: 18654572 DOI: 10.1038/nri2377]
-
(2008)
Nat Rev Immunol
, vol.8
, pp. 644-654
-
-
Katze, M.G.1
Fornek, J.L.2
Palermo, R.E.3
Walters, K.A.4
Korth, M.J.5
-
66
-
-
84876430637
-
Cell-based genomic screening: elucidating virus-host interactions
-
[PMID: 23122855]
-
Panda D, Cherry S. Cell-based genomic screening: elucidating virus-host interactions. Curr Opin Virol 2012; 2: 784-792 [PMID: 23122855 DOI: 10.1016/j.coviro.2012.10.007]
-
(2012)
Curr Opin Virol
, vol.2
, pp. 784-792
-
-
Panda, D.1
Cherry, S.2
-
67
-
-
66149128094
-
Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication
-
[PMID: 19376974]
-
Berger KL, Cooper JD, Heaton NS, Yoon R, Oakland TE, Jordan TX, Mateu G, Grakoui A, Randall G. Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication. Proc Natl Acad Sci USA 2009; 106: 7577-7582 [PMID: 19376974 DOI: 10.1073/pnas.0902693106]
-
(2009)
Proc Natl Acad Sci USA
, vol.106
, pp. 7577-7582
-
-
Berger, K.L.1
Cooper, J.D.2
Heaton, N.S.3
Yoon, R.4
Oakland, T.E.5
Jordan, T.X.6
Mateu, G.7
Grakoui, A.8
Randall, G.9
-
68
-
-
79955692689
-
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy
-
[PMID: 21516087]
-
Lupberger J, Zeisel MB, Xiao F, Thumann C, Fofana I, Zona L, Davis C, Mee CJ, Turek M, Gorke S, Royer C, Fischer B, Zahid MN, Lavillette D, Fresquet J, Cosset FL, Rothenberg SM, Pietschmann T, Patel AH, Pessaux P, Doffoël M, Raffelsberger W, Poch O, McKeating JA, Brino L, Baumert TF. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med 2011; 17: 589-595 [PMID: 21516087 DOI: 10.1038/nm.2341]
-
(2011)
Nat Med
, vol.17
, pp. 589-595
-
-
Lupberger, J.1
Zeisel, M.B.2
Xiao, F.3
Thumann, C.4
Fofana, I.5
Zona, L.6
Davis, C.7
Mee, C.J.8
Turek, M.9
Gorke, S.10
Royer, C.11
Fischer, B.12
Zahid, M.N.13
Lavillette, D.14
Fresquet, J.15
Cosset, F.L.16
Rothenberg, S.M.17
Pietschmann, T.18
Patel, A.H.19
Pessaux, P.20
Doffoël, M.21
Raffelsberger, W.22
Poch, O.23
McKeating, J.A.24
Brino, L.25
Baumert, T.F.26
more..
-
69
-
-
78751512667
-
Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment
-
[PMID: 21238945]
-
Reiss S, Rebhan I, Backes P, Romero-Brey I, Erfle H, Matula P, Kaderali L, Poenisch M, Blankenburg H, Hiet MS, Longerich T, Diehl S, Ramirez F, Balla T, Rohr K, Kaul A, Bühler S, Pepperkok R, Lengauer T, Albrecht M, Eils R, Schirmacher P, Lohmann V, Bartenschlager R. Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microbe 2011; 9: 32-45 [PMID: 21238945 DOI: 10.1016/j.chom.2010.12.002]
-
(2011)
Cell Host Microbe
, vol.9
, pp. 32-45
-
-
Reiss, S.1
Rebhan, I.2
Backes, P.3
Romero-Brey, I.4
Erfle, H.5
Matula, P.6
Kaderali, L.7
Poenisch, M.8
Blankenburg, H.9
Hiet, M.S.10
Longerich, T.11
Diehl, S.12
Ramirez, F.13
Balla, T.14
Rohr, K.15
Kaul, A.16
Bühler, S.17
Pepperkok, R.18
Lengauer, T.19
Albrecht, M.20
Eils, R.21
Schirmacher, P.22
Lohmann, V.23
Bartenschlager, R.24
more..
-
70
-
-
0032585237
-
Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
-
[PMID: 9807989]
-
Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT) Lancet 1998; 352: 1426-1432 [PMID: 9807989 DOI: 10.1016/S0140-6736(98)07124-4]
-
(1998)
International Hepatitis Interventional Therapy Group (IHIT) Lancet
, vol.352
, pp. 1426-1432
-
-
Poynard, T.1
Marcellin, P.2
Lee, S.S.3
Niederau, C.4
Minuk, G.S.5
Ideo, G.6
Bain, V.7
Heathcote, J.8
Zeuzem, S.9
Trepo, C.10
Albrecht, J.11
-
71
-
-
84908425544
-
Individualized treatment of genotype 1 naïve patients: an Italian multicenter field practice experience
-
[PMID: 25340799]
-
Mangia A, Cenderello G, Orlandini A, Piazzolla V, Picciotto A, Zuin M, Ciancio A, Brancaccio G, Forte P, Carretta V, Zignego AL, Minerva N, Brindicci G, Marignani M, Baroni GS, Bertino G, Cuccorese G, Mottola L, Ripoli M, Pirisi M. Individualized treatment of genotype 1 naïve patients: an Italian multicenter field practice experience. PLoS One 2014; 9: e110284 [PMID: 25340799 DOI: 10.1371/journal.pone.0110284]
-
(2014)
PLoS One
, vol.9
-
-
Mangia, A.1
Cenderello, G.2
Orlandini, A.3
Piazzolla, V.4
Picciotto, A.5
Zuin, M.6
Ciancio, A.7
Brancaccio, G.8
Forte, P.9
Carretta, V.10
Zignego, A.L.11
Minerva, N.12
Brindicci, G.13
Marignani, M.14
Baroni, G.S.15
Bertino, G.16
Cuccorese, G.17
Mottola, L.18
Ripoli, M.19
Pirisi, M.20
more..
-
72
-
-
84872038038
-
Interferon free therapy with direct acting antivirals for HCV
-
[PMID: 23286852]
-
Asselah T, Marcellin P. Interferon free therapy with direct acting antivirals for HCV. Liver Int 2013; 33 Suppl 1: 93-104 [PMID: 23286852 DOI: 10.1111/liv.12076]
-
(2013)
Liver Int
, vol.33
, pp. 93-104
-
-
Asselah, T.1
Marcellin, P.2
-
73
-
-
84878976866
-
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial
-
[PMID: 23499440]
-
Kowdley KV, Lawitz E, Crespo I, Hassanein T, Davis MN, DeMicco M, Bernstein DE, Afdhal N, Vierling JM, Gordon SC, Anderson JK, Hyland RH, Dvory-Sobol H, An D, Hindes RG, Albanis E, Symonds WT, Berrey MM, Nelson DR, Jacobson IM. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013; 381: 2100-2107 [PMID: 23499440 DOI: 10.1016/S0140-6736(13)60247-0]
-
(2013)
Lancet
, vol.381
, pp. 2100-2107
-
-
Kowdley, K.V.1
Lawitz, E.2
Crespo, I.3
Hassanein, T.4
Davis, M.N.5
DeMicco, M.6
Bernstein, D.E.7
Afdhal, N.8
Vierling, J.M.9
Gordon, S.C.10
Anderson, J.K.11
Hyland, R.H.12
Dvory-Sobol, H.13
An, D.14
Hindes, R.G.15
Albanis, E.16
Symonds, W.T.17
Berrey, M.M.18
Nelson, D.R.19
Jacobson, I.M.20
more..
-
74
-
-
84888295678
-
Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study
-
[PMID: 23907700]
-
Fried MW, Buti M, Dore GJ, Flisiak R, Ferenci P, Jacobson I, Marcellin P, Manns M, Nikitin I, Poordad F, Sherman M, Zeuzem S, Scott J, Gilles L, Lenz O, Peeters M, Sekar V, De Smedt G, Beumont-Mauviel M. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013; 58: 1918-1929 [PMID: 23907700 DOI: 10.1002/hep.26641]
-
(2013)
Hepatology
, vol.58
, pp. 1918-1929
-
-
Fried, M.W.1
Buti, M.2
Dore, G.J.3
Flisiak, R.4
Ferenci, P.5
Jacobson, I.6
Marcellin, P.7
Manns, M.8
Nikitin, I.9
Poordad, F.10
Sherman, M.11
Zeuzem, S.12
Scott, J.13
Gilles, L.14
Lenz, O.15
Peeters, M.16
Sekar, V.17
De Smedt, G.18
Beumont-Mauviel, M.19
-
75
-
-
84862161013
-
Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents
-
[PMID: 22676357]
-
Poordad F, Dieterich D. Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents. J Viral Hepat 2012;19: 449-464 [PMID: 22676357 DOI: 10.1111/j.1365-2893.2012.01617.x]
-
(2012)
J Viral Hepat
, vol.19
, pp. 449-464
-
-
Poordad, F.1
Dieterich, D.2
-
76
-
-
77953416889
-
New direct-acting antivirals in the development for hepatitis C virus infection
-
[PMID: 21180601]
-
Pockros PJ. New direct-acting antivirals in the development for hepatitis C virus infection. Therap Adv Gastroenterol 2010; 3: 191-202 [PMID: 21180601 DOI: 10.1177/1756283X10363055]
-
(2010)
Therap Adv Gastroenterol
, vol.3
, pp. 191-202
-
-
Pockros, P.J.1
-
77
-
-
84918777974
-
Boceprevir and telaprevir for chronic genotype 1 hepatitis C virus infection. A systematic review and meta-analysis
-
[PMID: 25536641]
-
Manzano-Robleda Mdel C, Ornelas-Arroyo V, Barrientos-Gutiérrez T, Méndez-Sánchez N, Uribe M, Chávez-Tapia NC. Boceprevir and telaprevir for chronic genotype 1 hepatitis C virus infection. A systematic review and meta-analysis. Ann Hepatol 2015;14: 46-57 [PMID: 25536641]
-
(2015)
Ann Hepatol
, vol.14
, pp. 46-57
-
-
Manzano-Robleda Mdel, C.1
Ornelas-Arroyo, V.2
Barrientos-Gutiérrez, T.3
Méndez-Sánchez, N.4
Uribe, M.5
Chávez-Tapia, N.C.6
-
78
-
-
79955103901
-
Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus
-
[PMID: 21374691]
-
Pawlotsky JM. Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 2011; 53: 1742-1751 [PMID: 21374691 DOI: 10.1002/hep.24262]
-
(2011)
Hepatology
, vol.53
, pp. 1742-1751
-
-
Pawlotsky, J.M.1
-
79
-
-
80053339008
-
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases
-
[PMID: 21898493]
-
Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-1444 [PMID: 21898493 DOI: 10.1002/hep.24641]
-
(2011)
Hepatology
, vol.54
, pp. 1433-1444
-
-
Ghany, M.G.1
Nelson, D.R.2
Strader, D.B.3
Thomas, D.L.4
Seeff, L.B.5
-
80
-
-
79953176289
-
Boceprevir for previously treated chronic HCV genotype 1 infection
-
[PMID: 21449784]
-
Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217 [PMID: 21449784 DOI: 10.1056/NEJMoa1009482]
-
(2011)
N Engl J Med
, vol.364
, pp. 1207-1217
-
-
Bacon, B.R.1
Gordon, S.C.2
Lawitz, E.3
Marcellin, P.4
Vierling, J.M.5
Zeuzem, S.6
Poordad, F.7
Goodman, Z.D.8
Sings, H.L.9
Boparai, N.10
Burroughs, M.11
Brass, C.A.12
Albrecht, J.K.13
Esteban, R.14
-
81
-
-
70349292099
-
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
-
[PMID: 19684573]
-
Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461: 399-401 [PMID: 19684573 DOI: 10.1038/nature08309]
-
(2009)
Nature
, vol.461
, pp. 399-401
-
-
Ge, D.1
Fellay, J.2
Thompson, A.J.3
Simon, J.S.4
Shianna, K.V.5
Urban, T.J.6
Heinzen, E.L.7
Qiu, P.8
Bertelsen, A.H.9
Muir, A.J.10
Sulkowski, M.11
McHutchison, J.G.12
Goldstein, D.B.13
-
82
-
-
84885308430
-
Drug-drug interactions during antiviral therapy for chronic hepatitis C
-
[PMID: 23817323]
-
Kiser JJ, Burton JR, Everson GT. Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol 2013; 10: 596-606 [PMID: 23817323 DOI: 10.1038/nrgastro.2013.106]
-
(2013)
Nat Rev Gastroenterol Hepatol
, vol.10
, pp. 596-606
-
-
Kiser, J.J.1
Burton, J.R.2
Everson, G.T.3
-
83
-
-
84871118829
-
What are the promising new therapies in the field of chronic hepatitis C after the first-generation directacting antivirals?
-
[PMID: 23250703]
-
Hunt D, Pockros P. What are the promising new therapies in the field of chronic hepatitis C after the first-generation directacting antivirals? Curr Gastroenterol Rep 2013; 15: 303 [PMID: 23250703 DOI: 10.1007/s11894-012-0303-3]
-
(2013)
Curr Gastroenterol Rep
, vol.15
, pp. 303
-
-
Hunt, D.1
Pockros, P.2
-
84
-
-
79960453276
-
EASL Clinical Practice Guidelines: management of hepatitis C virus infection
-
[PMID: 21371579]
-
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264 [PMID: 21371579 DOI: 10.1016/j.jhep.2011.02.023]
-
(2011)
J Hepatol
, vol.55
, pp. 245-264
-
-
-
85
-
-
84925511627
-
Simeprevir: a review of its use in patients with chronic hepatitis C virus infection
-
[PMID: 25559421]
-
Sanford M. Simeprevir: a review of its use in patients with chronic hepatitis C virus infection. Drugs 2015; 75: 183-196 [PMID: 25559421 DOI: 10.1007/s40265-014-0341-2]
-
(2015)
Drugs
, vol.75
, pp. 183-196
-
-
Sanford, M.1
-
86
-
-
0036320872
-
Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7
-
[PMID: 12124305]
-
Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, Wrighton SA. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 2002; 30: 883-891 [PMID: 12124305 DOI: 10.1124/dmd.30.8.883]
-
(2002)
Drug Metab Dispos
, vol.30
, pp. 883-891
-
-
Williams, J.A.1
Ring, B.J.2
Cantrell, V.E.3
Jones, D.R.4
Eckstein, J.5
Ruterbories, K.6
Hamman, M.A.7
Hall, S.D.8
Wrighton, S.A.9
-
87
-
-
84925357051
-
Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysis
-
[PMID: 25641426]
-
Perumpail RB, Wong RJ, Ha LD, Pham EA, Wang U, Luong H, Kumari R, Daugherty TJ, Higgins JP, Younossi ZM, Kim WR, Glenn JS, Ahmed A. Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and hemodialysis. Transpl Infect Dis 2015; 17: 275-278 [PMID: 25641426 DOI: 10.1111/tid.12348]
-
(2015)
Transpl Infect Dis
, vol.17
, pp. 275-278
-
-
Perumpail, R.B.1
Wong, R.J.2
Ha, L.D.3
Pham, E.A.4
Wang, U.5
Luong, H.6
Kumari, R.7
Daugherty, T.J.8
Higgins, J.P.9
Younossi, Z.M.10
Kim, W.R.11
Glenn, J.S.12
Ahmed, A.13
-
88
-
-
84907447002
-
O7 Once-daily simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype 1 prior null responders with Metavir F0-2: COSMOS study subgroup analysis
-
Sulkowski M, Jacobson IM, Ghalib R, Rodriguez-Torres M, Younossi Z, Corregidor A, Fevery B, Callewaert K, Symonds W, De La Rosa G, Picchio G, Ouwerkerk-Mahadevan S, Lambrecht T, Lawitz E. O7 Once-daily simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype 1 prior null responders with Metavir F0-2: COSMOS study subgroup analysis. J Hepatol 2014; 60: S4 [DOI: 10.1016/S0168-8278(14)60009-X]
-
(2014)
J Hepatol
, vol.60
, pp. S4
-
-
Sulkowski, M.1
Jacobson, I.M.2
Ghalib, R.3
Rodriguez-Torres, M.4
Younossi, Z.5
Corregidor, A.6
Fevery, B.7
Callewaert, K.8
Symonds, W.9
De La Rosa, G.10
Picchio, G.11
Ouwerkerk-Mahadevan, S.12
Lambrecht, T.13
Lawitz, E.14
-
89
-
-
84954406089
-
Simeprevir plus sofosbuvir with/without ribavirin in HCV genotype 1 prior nullresponder/treatment-naive patients (COSMOS study): primary endpoint (SVR12) results in patients with METAVIR F3-4 (Cohort 2)
-
49th Annual Meeting of the European Association for the Study of the Liver. London (UK), [Accessed 2014 Jun 25]
-
Lawitz E, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, Sulkowski MS, DeJesus E, Pearlman B, Rabinovitz M, Gitlin M, Lim JK, Pockros PJ, Fevery B, Lambrecht T, Ouwerkerk-Mahadevan S, Callewaert K, Symonds WT, Picchio G, Lindsay K, Beumont-Mauviel M, Jacobson IM. Simeprevir plus sofosbuvir with/without ribavirin in HCV genotype 1 prior nullresponder/treatment-naive patients (COSMOS study): primary endpoint (SVR12) results in patients with METAVIR F3-4 (Cohort 2). Abstract presented at: EASL - The International Liver Congress. 49th Annual Meeting of the European Association for the Study of the Liver. London (UK), 2014. [Accessed 2014 Jun 25]. Available from: URL: http://www.natap.org/2014/EASL/EASL_26.htm
-
(2014)
Abstract presented at: EASL - The International Liver Congress
-
-
Lawitz, E.1
Ghalib, R.2
Rodriguez-Torres, M.3
Younossi, Z.M.4
Corregidor, A.5
Sulkowski, M.S.6
DeJesus, E.7
Pearlman, B.8
Rabinovitz, M.9
Gitlin, M.10
Lim, J.K.11
Pockros, P.J.12
Fevery, B.13
Lambrecht, T.14
Ouwerkerk-Mahadevan, S.15
Callewaert, K.16
Symonds, W.T.17
Picchio, G.18
Lindsay, K.19
Beumont-Mauviel, M.20
Jacobson, I.M.21
more..
-
90
-
-
84922921833
-
O66 Sofosbuvir-based regimens are associated with high SVR rates across genotypes and among patients with multiple negative predictive factors
-
Foster GR, Strasser S, Christensen C, Ma J, Bekele BN, Brainard DM, Symonds WT, McHutchison JG, Conway B, Crespo I, Zeuzem S. O66 Sofosbuvir-based regimens are associated with high SVR rates across genotypes and among patients with multiple negative predictive factors. J Hepatol 2014; 60: S27 [DOI: 10.1016/S0168-8278(14)60068-4]
-
(2014)
J Hepatol
, vol.60
, pp. S27
-
-
Foster, G.R.1
Strasser, S.2
Christensen, C.3
Ma, J.4
Bekele, B.N.5
Brainard, D.M.6
Symonds, W.T.7
McHutchison, J.G.8
Conway, B.9
Crespo, I.10
Zeuzem, S.11
-
91
-
-
84925411319
-
The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis
-
quiz e11-12 [PMID: 25557952]
-
Pearlman BL, Ehleben C, Perrys M. The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis. Gastroenterology 2015; 148: 762-770.e2; quiz e11-12 [PMID: 25557952 DOI: 10.1053/j.gastro.2014.12.027]
-
(2015)
Gastroenterology
, vol.148
, pp. 762-770.e2
-
-
Pearlman, B.L.1
Ehleben, C.2
Perrys, M.3
-
92
-
-
84906053496
-
Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial
-
[PMID: 24907225]
-
Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, Moroz L, Craxi A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Scott J, Sinha R, Beumont-Mauviel M. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2014; 384: 403-413 [PMID: 24907225 DOI: 10.1016/S0140-6736(14)60494-3]
-
(2014)
Lancet
, vol.384
, pp. 403-413
-
-
Jacobson, I.M.1
Dore, G.J.2
Foster, G.R.3
Fried, M.W.4
Radu, M.5
Rafalsky, V.V.6
Moroz, L.7
Craxi, A.8
Peeters, M.9
Lenz, O.10
Ouwerkerk-Mahadevan, S.11
De La Rosa, G.12
Kalmeijer, R.13
Scott, J.14
Sinha, R.15
Beumont-Mauviel, M.16
-
93
-
-
84906059095
-
Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial
-
[PMID: 24907224]
-
Manns M, Marcellin P, Poordad F, de Araujo ES, Buti M, Horsmans Y, Janczewska E, Villamil F, Scott J, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, De La Rosa G, Kalmeijer R, Sinha R, Beumont-Mauviel M. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2014; 384: 414-426 [PMID: 24907224 DOI: 10.1016/S0140-6736(14)60538-9]
-
(2014)
Lancet
, vol.384
, pp. 414-426
-
-
Manns, M.1
Marcellin, P.2
Poordad, F.3
de Araujo, E.S.4
Buti, M.5
Horsmans, Y.6
Janczewska, E.7
Villamil, F.8
Scott, J.9
Peeters, M.10
Lenz, O.11
Ouwerkerk-Mahadevan, S.12
De La Rosa, G.13
Kalmeijer, R.14
Sinha, R.15
Beumont-Mauviel, M.16
-
94
-
-
84901217985
-
Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial
-
[PMID: 24602923]
-
Forns X, Lawitz E, Zeuzem S, Gane E, Bronowicki JP, Andreone P, Horban A, Brown A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, Scott J, De La Rosa G, Kalmeijer R, Sinha R, Beumont-Mauviel M. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014; 146: 1669-79.e3 [PMID: 24602923 DOI: 10.1053/j.gastro.2014.02.051]
-
(2014)
Gastroenterology
, vol.146
, pp. 1669-79.e3
-
-
Forns, X.1
Lawitz, E.2
Zeuzem, S.3
Gane, E.4
Bronowicki, J.P.5
Andreone, P.6
Horban, A.7
Brown, A.8
Peeters, M.9
Lenz, O.10
Ouwerkerk-Mahadevan, S.11
Scott, J.12
De La Rosa, G.13
Kalmeijer, R.14
Sinha, R.15
Beumont-Mauviel, M.16
-
95
-
-
84904723744
-
Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial
-
[PMID: 24727123]
-
Hayashi N, Izumi N, Kumada H, Okanoue T, Tsubouchi H, Yatsuhashi H, Kato M, Ki R, Komada Y, Seto C, Goto S. Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial. J Hepatol 2014; 61: 219-227 [PMID: 24727123 DOI: 10.1016/j.jhep.2014.04.004]
-
(2014)
J Hepatol
, vol.61
, pp. 219-227
-
-
Hayashi, N.1
Izumi, N.2
Kumada, H.3
Okanoue, T.4
Tsubouchi, H.5
Yatsuhashi, H.6
Kato, M.7
Ki, R.8
Komada, Y.9
Seto, C.10
Goto, S.11
-
96
-
-
84901451695
-
Oncedaily simeprevir with peginterferon and ribavirin for treatmentexperienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies
-
[PMID: 24626851]
-
Izumi N, Hayashi N, Kumada H, Okanoue T, Tsubouchi H, Yatsuhashi H, Kato M, Ki R, Komada Y, Seto C, Goto S. Oncedaily simeprevir with peginterferon and ribavirin for treatmentexperienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies. J Gastroenterol 2014; 49: 941-953 [PMID: 24626851 DOI: 10.1007/s00535-014-0949-8]
-
(2014)
J Gastroenterol
, vol.49
, pp. 941-953
-
-
Izumi, N.1
Hayashi, N.2
Kumada, H.3
Okanoue, T.4
Tsubouchi, H.5
Yatsuhashi, H.6
Kato, M.7
Ki, R.8
Komada, Y.9
Seto, C.10
Goto, S.11
-
97
-
-
84928203902
-
Simeprevir (TMC435) once daily with peginterferon-a-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO-4 study
-
[PMID: 24961662]
-
Kumada H, Hayashi N, Izumi N, Okanoue T, Tsubouchi H, Yatsuhashi H, Kato M, Rito K, Komada Y, Seto C, Goto S. Simeprevir (TMC435) once daily with peginterferon-a-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO-4 study. Hepatol Res 2015; 45: 501-513 [PMID: 24961662 DOI: 10.1111/hepr.12375]
-
(2015)
Hepatol Res
, vol.45
, pp. 501-513
-
-
Kumada, H.1
Hayashi, N.2
Izumi, N.3
Okanoue, T.4
Tsubouchi, H.5
Yatsuhashi, H.6
Kato, M.7
Rito, K.8
Komada, Y.9
Seto, C.10
Goto, S.11
-
98
-
-
84878992253
-
Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial
-
[PMID: 23359516]
-
Sulkowski MS, Asselah T, Lalezari J, Ferenci P, Fainboim H, Leggett B, Bessone F, Mauss S, Heo J, Datsenko Y, Stern JO, Kukolj G, Scherer J, Nehmiz G, Steinmann GG, Böcher WO. Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial. Hepatology 2013; 57: 2143-2154 [PMID: 23359516 DOI: 10.1002/hep.26276]
-
(2013)
Hepatology
, vol.57
, pp. 2143-2154
-
-
Sulkowski, M.S.1
Asselah, T.2
Lalezari, J.3
Ferenci, P.4
Fainboim, H.5
Leggett, B.6
Bessone, F.7
Mauss, S.8
Heo, J.9
Datsenko, Y.10
Stern, J.O.11
Kukolj, G.12
Scherer, J.13
Nehmiz, G.14
Steinmann, G.G.15
Böcher, W.O.16
-
99
-
-
84890126935
-
Safety and efficacy of faldaprevir with pegylated interferon alfa-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection
-
[PMID: 23944720]
-
Nishiguchi S, Sakai Y, Kuboki M, Tsunematsu S, Urano Y, Sakamoto W, Tsuda Y, Steinmann G, Omata M. Safety and efficacy of faldaprevir with pegylated interferon alfa-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection. Liver Int 2014; 34: 78-88 [PMID: 23944720 DOI: 10.1111/liv.12254]
-
(2014)
Liver Int
, vol.34
, pp. 78-88
-
-
Nishiguchi, S.1
Sakai, Y.2
Kuboki, M.3
Tsunematsu, S.4
Urano, Y.5
Sakamoto, W.6
Tsuda, Y.7
Steinmann, G.8
Omata, M.9
-
100
-
-
81855228070
-
Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection
-
quiz e14 [PMID: 21925126]
-
Zeuzem S, Asselah T, Angus P, Zarski JP, Larrey D, Müllhaupt B, Gane E, Schuchmann M, Lohse A, Pol S, Bronowicki JP, Roberts S, Arasteh K, Zoulim F, Heim M, Stern JO, Kukolj G, Nehmiz G, Haefner C, Boecher WO. Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology 2011; 141: 2047-2055; quiz e14 [PMID: 21925126 DOI: 10.1053/j.gastro.2011.08.051]
-
(2011)
Gastroenterology
, vol.141
, pp. 2047-2055
-
-
Zeuzem, S.1
Asselah, T.2
Angus, P.3
Zarski, J.P.4
Larrey, D.5
Müllhaupt, B.6
Gane, E.7
Schuchmann, M.8
Lohse, A.9
Pol, S.10
Bronowicki, J.P.11
Roberts, S.12
Arasteh, K.13
Zoulim, F.14
Heim, M.15
Stern, J.O.16
Kukolj, G.17
Nehmiz, G.18
Haefner, C.19
Boecher, W.O.20
more..
-
101
-
-
84881405876
-
Faldaprevir and deleobuvir for HCV genotype 1 infection
-
[PMID: 23944300]
-
Zeuzem S, Soriano V, Asselah T, Bronowicki JP, Lohse AW, Müllhaupt B, Schuchmann M, Bourlière M, Buti M, Roberts SK, Gane EJ, Stern JO, Vinisko R, Kukolj G, Gallivan JP, Böcher WO, Mensa FJ. Faldaprevir and deleobuvir for HCV genotype 1 infection. N Engl J Med 2013; 369: 630-639 [PMID: 23944300 DOI: 10.1056/NEJMoa1213557]
-
(2013)
N Engl J Med
, vol.369
, pp. 630-639
-
-
Zeuzem, S.1
Soriano, V.2
Asselah, T.3
Bronowicki, J.P.4
Lohse, A.W.5
Müllhaupt, B.6
Schuchmann, M.7
Bourlière, M.8
Buti, M.9
Roberts, S.K.10
Gane, E.J.11
Stern, J.O.12
Vinisko, R.13
Kukolj, G.14
Gallivan, J.P.15
Böcher, W.O.16
Mensa, F.J.17
-
102
-
-
84888210472
-
Antiviral therapy for "difficult-to-treat" hepatitis C virus-infected patients
-
[PMID: 24286427]
-
Kanda T, Yokosuka O, Omata M. Antiviral therapy for "difficult-to-treat" hepatitis C virus-infected patients. Chin Med J (Engl) 2013;126: 4568-4574 [PMID: 24286427]
-
(2013)
Chin Med J (Engl)
, vol.126
, pp. 4568-4574
-
-
Kanda, T.1
Yokosuka, O.2
Omata, M.3
-
103
-
-
84931569160
-
Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial
-
[PMID: 25837829]
-
Hézode C, Asselah T, Reddy KR, Hassanein T, Berenguer M, Fleischer-Stepniewska K, Marcellin P, Hall C, Schnell G, Pilot-Matias T, Mobashery N, Redman R, Vilchez RA, Pol S. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet 2015; 385: 2502-2509 [PMID: 25837829 DOI: 10.1016/S0140-6736(15)60159-3]
-
(2015)
Lancet
, vol.385
, pp. 2502-2509
-
-
Hézode, C.1
Asselah, T.2
Reddy, K.R.3
Hassanein, T.4
Berenguer, M.5
Fleischer-Stepniewska, K.6
Marcellin, P.7
Hall, C.8
Schnell, G.9
Pilot-Matias, T.10
Mobashery, N.11
Redman, R.12
Vilchez, R.A.13
Pol, S.14
-
104
-
-
42949145532
-
Regulation of hepatitis C virion production via phosphorylation of the NS5A protein
-
[PMID: 18369478]
-
Tellinghuisen TL, Foss KL, Treadaway J. Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. PLoS Pathog 2008; 4: e1000032 [PMID: 18369478 DOI: 10.1371/journal.ppat.1000032]
-
(2008)
PLoS Pathog
, vol.4
-
-
Tellinghuisen, T.L.1
Foss, K.L.2
Treadaway, J.3
-
105
-
-
84907518030
-
Discovery of novel highly potent hepatitis C virus NS5A inhibitor (AV4025)
-
[PMID: 25148100]
-
Ivachtchenko AV, Mitkin OD, Yamanushkin PM, Kuznetsova IV, Bulanova EA, Shevkun NA, Koryakova AG, Karapetian RN, Bichko VV, Trifelenkov AS, Kravchenko DV, Vostokova NV, Veselov MS, Chufarova NV, Ivanenkov YA. Discovery of novel highly potent hepatitis C virus NS5A inhibitor (AV4025). J Med Chem 2014; 57: 7716-7730 [PMID: 25148100 DOI: 10.1021/jm500951r]
-
(2014)
J Med Chem
, vol.57
, pp. 7716-7730
-
-
Ivachtchenko, A.V.1
Mitkin, O.D.2
Yamanushkin, P.M.3
Kuznetsova, I.V.4
Bulanova, E.A.5
Shevkun, N.A.6
Koryakova, A.G.7
Karapetian, R.N.8
Bichko, V.V.9
Trifelenkov, A.S.10
Kravchenko, D.V.11
Vostokova, N.V.12
Veselov, M.S.13
Chufarova, N.V.14
Ivanenkov, Y.A.15
-
106
-
-
84925364974
-
All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study
-
[PMID: 25614962]
-
Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, Freilich BF, Younes ZH, Harlan W, Ghalib R, Oguchi G, Thuluvath PJ, Ortiz-Lasanta G, Rabinovitz M, Bernstein D, Bennett M, Hawkins T, Ravendhran N, Sheikh AM, Varunok P, Kowdley KV, Hennicken D, McPhee F, Rana K, Hughes EA. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015;61: 1127-1135 [PMID: 25614962 DOI: 10.1002/hep.27726]
-
(2015)
Hepatology
, vol.61
, pp. 1127-1135
-
-
Nelson, D.R.1
Cooper, J.N.2
Lalezari, J.P.3
Lawitz, E.4
Pockros, P.J.5
Gitlin, N.6
Freilich, B.F.7
Younes, Z.H.8
Harlan, W.9
Ghalib, R.10
Oguchi, G.11
Thuluvath, P.J.12
Ortiz-Lasanta, G.13
Rabinovitz, M.14
Bernstein, D.15
Bennett, M.16
Hawkins, T.17
Ravendhran, N.18
Sheikh, A.M.19
Varunok, P.20
Kowdley, K.V.21
Hennicken, D.22
McPhee, F.23
Rana, K.24
Hughes, E.A.25
more..
-
107
-
-
84884223989
-
Daclatasvir combined with peginterferon alfa-2A and ribavirin for 12 or 16 weeks in patients with HCV genotype 2 or 3 infection: COMMAND GT2/3 STUDY
-
Dore GJ, Lawitz E, H'ezode C, Shafran S, Ramji A, Tatum H, Taliani G, Tran A, Brunetto M, Zaltron S, Strasser S, Weis N, Ghesquiere W, Lee S, Larrey D, Pol S, Harley H, George J, Fung S, de L'edinghen V, Hagens P, Cohen D, Cooney E, Noviello S, Hughes E. Daclatasvir combined with peginterferon alfa-2A and ribavirin for 12 or 16 weeks in patients with HCV genotype 2 or 3 infection: COMMAND GT2/3 STUDY. J Hepatol 2013; 58 (suppl 1): S570-571 [DOI: 10.1016/S0168-8278(13)61417-8]
-
(2013)
J Hepatol
, vol.58
, pp. S570-571
-
-
Dore, G.J.1
Lawitz, E.2
H'ezode, C.3
Shafran, S.4
Ramji, A.5
Tatum, H.6
Taliani, G.7
Tran, A.8
Brunetto, M.9
Zaltron, S.10
Strasser, S.11
Weis, N.12
Ghesquiere, W.13
Lee, S.14
Larrey, D.15
Pol, S.16
Harley, H.17
George, J.18
Fung, S.19
de L'edinghen, V.20
Hagens, P.21
Cohen, D.22
Cooney, E.23
Noviello, S.24
Hughes, E.25
more..
-
108
-
-
84892619580
-
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection
-
[PMID: 24428467]
-
Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, Lawitz E, Lok AS, Hinestrosa F, Thuluvath PJ, Schwartz H, Nelson DR, Everson GT, Eley T, Wind-Rotolo M, Huang SP, Gao M, Hernandez D, McPhee F, Sherman D, Hindes R, Symonds W, Pasquinelli C, Grasela DM. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370: 211-221 [PMID: 24428467 DOI: 10.1056/NEJMoa1306218]
-
(2014)
N Engl J Med
, vol.370
, pp. 211-221
-
-
Sulkowski, M.S.1
Gardiner, D.F.2
Rodriguez-Torres, M.3
Reddy, K.R.4
Hassanein, T.5
Jacobson, I.6
Lawitz, E.7
Lok, A.S.8
Hinestrosa, F.9
Thuluvath, P.J.10
Schwartz, H.11
Nelson, D.R.12
Everson, G.T.13
Eley, T.14
Wind-Rotolo, M.15
Huang, S.P.16
Gao, M.17
Hernandez, D.18
McPhee, F.19
Sherman, D.20
Hindes, R.21
Symonds, W.22
Pasquinelli, C.23
Grasela, D.M.24
more..
-
109
-
-
84862684876
-
A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C
-
[PMID: 22314425]
-
Lawitz EJ, Gruener D, Hill JM, Marbury T, Moorehead L, Mathias A, Cheng G, Link JO, Wong KA, Mo H, McHutchison JG, Brainard DM. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. J Hepatol 2012; 57: 24-31 [PMID: 22314425 DOI: 10.1016/j.jhep.2011.12.029]
-
(2012)
J Hepatol
, vol.57
, pp. 24-31
-
-
Lawitz, E.J.1
Gruener, D.2
Hill, J.M.3
Marbury, T.4
Moorehead, L.5
Mathias, A.6
Cheng, G.7
Link, J.O.8
Wong, K.A.9
Mo, H.10
McHutchison, J.G.11
Brainard, D.M.12
-
110
-
-
84870431451
-
1206 ABT-072 or ABT-333 combined with pegylated interferon/ribavirin after 3-day monotherapy in HCV genotype 1 (GT1)- infected treatment-naive subjects: 12-week sustained virologic response (SVR12) and safety results
-
Poordad F, Lawitz E, DeJesus E, Kowdley KN, Gaultier I, Cohen DE, Xie W, Larsen L, Pilot-Matias T, Koev G, Dumas D, Podsadecki T, Bernstein B. 1206 ABT-072 or ABT-333 combined with pegylated interferon/ribavirin after 3-day monotherapy in HCV genotype 1 (GT1)- infected treatment-naive subjects: 12-week sustained virologic response (SVR12) and safety results. J Hepatol 2012; 56 Suppl 2: S478 [DOI: 10.1016/S0168-8278(12)61218-5]
-
(2012)
J Hepatol
, vol.56
, pp. S478
-
-
Poordad, F.1
Lawitz, E.2
DeJesus, E.3
Kowdley, K.N.4
Gaultier, I.5
Cohen, D.E.6
Xie, W.7
Larsen, L.8
Pilot-Matias, T.9
Koev, G.10
Dumas, D.11
Podsadecki, T.12
Bernstein, B.13
-
111
-
-
84899068302
-
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin
-
[PMID: 24720703]
-
Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, Weiland O, Aguilar H, Xiong J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370: 1594-1603 [PMID: 24720703 DOI: 10.1056/NEJMoa1315722]
-
(2014)
N Engl J Med
, vol.370
, pp. 1594-1603
-
-
Feld, J.J.1
Kowdley, K.V.2
Coakley, E.3
Sigal, S.4
Nelson, D.R.5
Crawford, D.6
Weiland, O.7
Aguilar, H.8
Xiong, J.9
Pilot-Matias, T.10
DaSilva-Tillmann, B.11
Larsen, L.12
Podsadecki, T.13
Bernstein, B.14
-
112
-
-
84899106124
-
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin
-
[PMID: 24720679]
-
Zeuzem S, Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourlière M, Sulkowski MS, Wedemeyer H, Tam E, Desmond P, Jensen DM, Di Bisceglie AM, Varunok P, Hassanein T, Xiong J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014; 370: 1604-1614 [PMID: 24720679 DOI: 10.1056/NEJMoa1401561]
-
(2014)
N Engl J Med
, vol.370
, pp. 1604-1614
-
-
Zeuzem, S.1
Jacobson, I.M.2
Baykal, T.3
Marinho, R.T.4
Poordad, F.5
Bourlière, M.6
Sulkowski, M.S.7
Wedemeyer, H.8
Tam, E.9
Desmond, P.10
Jensen, D.M.11
Di Bisceglie, A.M.12
Varunok, P.13
Hassanein, T.14
Xiong, J.15
Pilot-Matias, T.16
DaSilva-Tillmann, B.17
Larsen, L.18
Podsadecki, T.19
Bernstein, B.20
more..
-
113
-
-
84901044326
-
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV
-
[PMID: 24795200]
-
Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, Marinho RT, Tsai N, Nyberg A, Box TD, Younes Z, Enayati P, Green S, Baruch Y, Bhandari BR, Caruntu FA, Sepe T, Chulanov V, Janczewska E, Rizzardini G, Gervain J, Planas R, Moreno C, Hassanein T, Xie W, King M, Podsadecki T, Reddy KR. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014; 370: 1983-1992 [PMID: 24795200 DOI: 10.1056/NEJMoa1402338]
-
(2014)
N Engl J Med
, vol.370
, pp. 1983-1992
-
-
Ferenci, P.1
Bernstein, D.2
Lalezari, J.3
Cohen, D.4
Luo, Y.5
Cooper, C.6
Tam, E.7
Marinho, R.T.8
Tsai, N.9
Nyberg, A.10
Box, T.D.11
Younes, Z.12
Enayati, P.13
Green, S.14
Baruch, Y.15
Bhandari, B.R.16
Caruntu, F.A.17
Sepe, T.18
Chulanov, V.19
Janczewska, E.20
Rizzardini, G.21
Gervain, J.22
Planas, R.23
Moreno, C.24
Hassanein, T.25
Xie, W.26
King, M.27
Podsadecki, T.28
Reddy, K.R.29
more..
-
114
-
-
84941933839
-
Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment
-
[PMID: 26070406]
-
Khatri A, Menon RM, Marbury TC, Lawitz EJ, Podsadecki TJ, Mullally VM, Ding B, Awni WM, Bernstein BM, Dutta S. Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment. J Hepatol 2015; 63: 805-812 [PMID: 26070406 DOI: 10.1016/j.jhep.2015.05.029]
-
(2015)
J Hepatol
, vol.63
, pp. 805-812
-
-
Khatri, A.1
Menon, R.M.2
Marbury, T.C.3
Lawitz, E.J.4
Podsadecki, T.J.5
Mullally, V.M.6
Ding, B.7
Awni, W.M.8
Bernstein, B.M.9
Dutta, S.10
-
115
-
-
84925362356
-
Tu2038 All Oral Fixed-dose Combination Sofosbuvir/Ledipasvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Naive Genotype 1 HCV-Infected Patients: The Phase 3 ION-1 Study
-
Jacobson IM, Marcellin P, Mangia A, Kwo PY, Foster G, Buti M, Brau N, Muir AJ, Yang JC, Mo H, Ding X, Pang P, Symonds WT, McHutchison JG, Zeuzem S, Afdhal NH. Tu2038 All Oral Fixed-dose Combination Sofosbuvir/Ledipasvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Naive Genotype 1 HCV-Infected Patients: The Phase 3 ION-1 Study. J Hepatol 2014; Supplement 60: S523-S524 [DOI: 10.1016/S0016-5085(14)63284-4]
-
(2014)
J Hepatol
, pp. S523-S524
-
-
Jacobson, I.M.1
Marcellin, P.2
Mangia, A.3
Kwo, P.Y.4
Foster, G.5
Buti, M.6
Brau, N.7
Muir, A.J.8
Yang, J.C.9
Mo, H.10
Ding, X.11
Pang, P.12
Symonds, W.T.13
McHutchison, J.G.14
Zeuzem, S.15
Afdhal, N.H.16
-
116
-
-
84900326091
-
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis
-
[PMID: 24720702]
-
Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, Shiffman ML, Schiff E, Ghalib R, Ryan M, Rustgi V, Chojkier M, Herring R, Di Bisceglie AM, Pockros PJ, Subramanian GM, An D, Svarovskaia E, Hyland RH, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Pound D, Fried MW. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370: 1879-1888 [PMID: 24720702 DOI: 10.1056/NEJMoa1402355]
-
(2014)
N Engl J Med
, vol.370
, pp. 1879-1888
-
-
Kowdley, K.V.1
Gordon, S.C.2
Reddy, K.R.3
Rossaro, L.4
Bernstein, D.E.5
Lawitz, E.6
Shiffman, M.L.7
Schiff, E.8
Ghalib, R.9
Ryan, M.10
Rustgi, V.11
Chojkier, M.12
Herring, R.13
Di Bisceglie, A.M.14
Pockros, P.J.15
Subramanian, G.M.16
An, D.17
Svarovskaia, E.18
Hyland, R.H.19
Pang, P.S.20
Symonds, W.T.21
McHutchison, J.G.22
Muir, A.J.23
Pound, D.24
Fried, M.W.25
more..
-
117
-
-
84898669547
-
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection
-
[PMID: 24725238]
-
Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-1493 [PMID: 24725238 DOI: 10.1056/NEJMoa1316366]
-
(2014)
N Engl J Med
, vol.370
, pp. 1483-1493
-
-
Afdhal, N.1
Reddy, K.R.2
Nelson, D.R.3
Lawitz, E.4
Gordon, S.C.5
Schiff, E.6
Nahass, R.7
Ghalib, R.8
Gitlin, N.9
Herring, R.10
Lalezari, J.11
Younes, Z.H.12
Pockros, P.J.13
Di Bisceglie, A.M.14
Arora, S.15
Subramanian, G.M.16
Zhu, Y.17
Dvory-Sobol, H.18
Yang, J.C.19
Pang, P.S.20
Symonds, W.T.21
McHutchison, J.G.22
Muir, A.J.23
Sulkowski, M.24
Kwo, P.25
more..
-
118
-
-
34548285424
-
Recent progress in the development of inhibitors of the hepatitis C virus RNA-dependent RNA polymerase
-
[PMID: 17627559]
-
Koch U, Narjes F. Recent progress in the development of inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. Curr Top Med Chem 2007; 7: 1302-1329 [PMID: 17627559 DOI: 10.2174/156802607781212211]
-
(2007)
Curr Top Med Chem
, vol.7
, pp. 1302-1329
-
-
Koch, U.1
Narjes, F.2
-
119
-
-
84877730954
-
Sofosbuvir for previously untreated chronic hepatitis C infection
-
[PMID: 23607594]
-
Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh AM, Younossi Z, Gane EJ. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-1887 [PMID: 23607594 DOI: 10.1056/NEJMoa1214853]
-
(2013)
N Engl J Med
, vol.368
, pp. 1878-1887
-
-
Lawitz, E.1
Mangia, A.2
Wyles, D.3
Rodriguez-Torres, M.4
Hassanein, T.5
Gordon, S.C.6
Schultz, M.7
Davis, M.N.8
Kayali, Z.9
Reddy, K.R.10
Jacobson, I.M.11
Kowdley, K.V.12
Nyberg, L.13
Subramanian, G.M.14
Hyland, R.H.15
Arterburn, S.16
Jiang, D.17
McNally, J.18
Brainard, D.19
Symonds, W.T.20
McHutchison, J.G.21
Sheikh, A.M.22
Younossi, Z.23
Gane, E.J.24
more..
-
120
-
-
84933671704
-
Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir
-
[PMID: 25822283]
-
Ki rby BJ, Symonds WT, Ke a rney BP, Ma thi a s AA. Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir. Clin Pharmacokinet 2015; 54: 677-690 [PMID: 25822283 DOI: 10.1007/s40262-015-0261-7]
-
(2015)
Clin Pharmacokinet
, vol.54
, pp. 677-690
-
-
Kirby, B.J.1
Symonds, W.T.2
Kearney, B.P.3
Mathias, A.A.4
-
121
-
-
84920410351
-
Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals
-
[PMID: 25608803]
-
Alexopoulou A, Karayiannis P. Interferon-based combination treatment for chronic hepatitis C in the era of direct acting antivirals. Ann Gastroenterol 2015; 28: 55-65 [PMID: 25608803]
-
(2015)
Ann Gastroenterol
, vol.28
, pp. 55-65
-
-
Alexopoulou, A.1
Karayiannis, P.2
-
122
-
-
84871814966
-
Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C
-
[PMID: 23281974]
-
Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, Hindes RG, Berrey MM. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368: 34-44 [PMID: 23281974 DOI: 10.1056/NEJMoa1208953]
-
(2013)
N Engl J Med
, vol.368
, pp. 34-44
-
-
Gane, E.J.1
Stedman, C.A.2
Hyland, R.H.3
Ding, X.4
Svarovskaia, E.5
Symonds, W.T.6
Hindes, R.G.7
Berrey, M.M.8
-
123
-
-
84880964894
-
Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatmentnaïve patients with HCV genotype 1: a randomized, 28-day, doseranging trial
-
[PMID: 23183528]
-
Rodriguez-Torres M, Lawitz E, Kowdley KV, Nelson DR, Dejesus E, McHutchison JG, Cornpropst MT, Mader M, Albanis E, Jiang D, Hebner CM, Symonds WT, Berrey MM, Lalezari J. Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatmentnaïve patients with HCV genotype 1: a randomized, 28-day, doseranging trial. J Hepatol 2013; 58: 663-668 [PMID: 23183528 DOI: 10.1016/j.jhep.2012.11.018]
-
(2013)
J Hepatol
, vol.58
, pp. 663-668
-
-
Rodriguez-Torres, M.1
Lawitz, E.2
Kowdley, K.V.3
Nelson, D.R.4
Dejesus, E.5
McHutchison, J.G.6
Cornpropst, M.T.7
Mader, M.8
Albanis, E.9
Jiang, D.10
Hebner, C.M.11
Symonds, W.T.12
Berrey, M.M.13
Lalezari, J.14
-
124
-
-
84923302656
-
Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis
-
[PMID: 25322962]
-
Lawitz E, Poordad F, Brainard DM, Hyland RH, An D, Dvory-Sobol H, Symonds WT, McHutchison JG, Membreno FE. Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis. Hepatology 2015; 61: 769-775 [PMID: 25322962 DOI: 10.1002/hep.27567]
-
(2015)
Hepatology
, vol.61
, pp. 769-775
-
-
Lawitz, E.1
Poordad, F.2
Brainard, D.M.3
Hyland, R.H.4
An, D.5
Dvory-Sobol, H.6
Symonds, W.T.7
McHutchison, J.G.8
Membreno, F.E.9
-
125
-
-
84894621765
-
Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial
-
[PMID: 24209977]
-
Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, Symonds WT, McHutchison JG, Membreno FE. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014; 383: 515-523 [PMID: 24209977 DOI: 10.1016/S0140-6736(13)62121-2]
-
(2014)
Lancet
, vol.383
, pp. 515-523
-
-
Lawitz, E.1
Poordad, F.F.2
Pang, P.S.3
Hyland, R.H.4
Ding, X.5
Mo, H.6
Symonds, W.T.7
McHutchison, J.G.8
Membreno, F.E.9
-
126
-
-
84877739274
-
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options
-
[PMID: 23607593]
-
Jacobson IM, Gordon SC, Kowdley KV, Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz E, Everson G, Bennett M, Schiff E, Al-Assi MT, Subramanian GM, An D, Lin M, McNally J, Brainard D, Symonds WT, McHutchison JG, Patel K, Feld J, Pianko S, Nelson DR. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-1877 [PMID: 23607593 DOI: 10.1056/NEJMoa1214854]
-
(2013)
N Engl J Med
, vol.368
, pp. 1867-1877
-
-
Jacobson, I.M.1
Gordon, S.C.2
Kowdley, K.V.3
Yoshida, E.M.4
Rodriguez-Torres, M.5
Sulkowski, M.S.6
Shiffman, M.L.7
Lawitz, E.8
Everson, G.9
Bennett, M.10
Schiff, E.11
Al-Assi, M.T.12
Subramanian, G.M.13
An, D.14
Lin, M.15
McNally, J.16
Brainard, D.17
Symonds, W.T.18
McHutchison, J.G.19
Patel, K.20
Feld, J.21
Pianko, S.22
Nelson, D.R.23
more..
-
127
-
-
84900992889
-
Sofosbuvir and ribavirin in HCV genotypes 2 and 3
-
[PMID: 24795201]
-
Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, Illeperuma A, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Weiland O, Reesink HW, Ferenci P, Hézode C, Esteban R. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370: 1993-2001 [PMID: 24795201 DOI: 10.1056/NEJMoa1316145]
-
(2014)
N Engl J Med
, vol.370
, pp. 1993-2001
-
-
Zeuzem, S.1
Dusheiko, G.M.2
Salupere, R.3
Mangia, A.4
Flisiak, R.5
Hyland, R.H.6
Illeperuma, A.7
Svarovskaia, E.8
Brainard, D.M.9
Symonds, W.T.10
Subramanian, G.M.11
McHutchison, J.G.12
Weiland, O.13
Reesink, H.W.14
Ferenci, P.15
Hézode, C.16
Esteban, R.17
-
128
-
-
84927796279
-
Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry
-
[PMID: 25450208]
-
Ruane PJ, Ain D, Stryker R, Meshrekey R, Soliman M, Wolfe PR, Riad J, Mikhail S, Kersey K, Jiang D, Massetto B, Doehle B, Kirby BJ, Knox SJ, McHutchison JG, Symonds WT. Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. J Hepatol 2015; 62: 1040-1046 [PMID: 25450208 DOI: 10.1016/j.jhep.2014.10.044]
-
(2015)
J Hepatol
, vol.62
, pp. 1040-1046
-
-
Ruane, P.J.1
Ain, D.2
Stryker, R.3
Meshrekey, R.4
Soliman, M.5
Wolfe, P.R.6
Riad, J.7
Mikhail, S.8
Kersey, K.9
Jiang, D.10
Massetto, B.11
Doehle, B.12
Kirby, B.J.13
Knox, S.J.14
McHutchison, J.G.15
Symonds, W.T.16
-
129
-
-
84899621215
-
Interferon-free strategies with a nucleoside/nucleotide analogue
-
[PMID: 24782257]
-
Feld JJ. Interferon-free strategies with a nucleoside/nucleotide analogue. Semin Liver Dis 2014; 34: 37-46 [PMID: 24782257 DOI: 10.1055/s-0034-1371009]
-
(2014)
Semin Liver Dis
, vol.34
, pp. 37-46
-
-
Feld, J.J.1
-
130
-
-
84890947330
-
Novel therapeutic approaches for hepatitis C
-
[PMID: 24126682]
-
Au JS, Pockros PJ. Novel therapeutic approaches for hepatitis C. Clin Pharmacol Ther 2014; 95: 78-88 [PMID: 24126682 DOI: 10.1038/clpt.2013.206]
-
(2014)
Clin Pharmacol Ther
, vol.95
, pp. 78-88
-
-
Au, J.S.1
Pockros, P.J.2
-
131
-
-
84901036125
-
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis
-
[PMID: 24725237]
-
Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, Shiffman ML, Wedemeyer H, Berg T, Yoshida EM, Forns X, Lovell SS, Da Silva-Tillmann B, Collins CA, Campbell AL, Podsadecki T, Bernstein B. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370: 1973-1982 [PMID: 24725237 DOI: 10.1056/NEJMoa1402869]
-
(2014)
N Engl J Med
, vol.370
, pp. 1973-1982
-
-
Poordad, F.1
Hezode, C.2
Trinh, R.3
Kowdley, K.V.4
Zeuzem, S.5
Agarwal, K.6
Shiffman, M.L.7
Wedemeyer, H.8
Berg, T.9
Yoshida, E.M.10
Forns, X.11
Lovell, S.S.12
Da Silva-Tillmann, B.13
Collins, C.A.14
Campbell, A.L.15
Podsadecki, T.16
Bernstein, B.17
-
132
-
-
84919654889
-
HCV cirrhosis at the edge of decompensation: will paritaprevir with ritonavir, ombitasvir, dasabuvir, and ribavirin solve the need for treatment?
-
[PMID: 25149112]
-
Asselah T, Bruno S, Craxi A. HCV cirrhosis at the edge of decompensation: will paritaprevir with ritonavir, ombitasvir, dasabuvir, and ribavirin solve the need for treatment? J Hepatol 2014; 61: 1430-1433 [PMID: 25149112 DOI: 10.1016/j.jhep.2014.08.018]
-
(2014)
J Hepatol
, vol.61
, pp. 1430-1433
-
-
Asselah, T.1
Bruno, S.2
Craxi, A.3
-
133
-
-
84904647749
-
ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatmentexperienced patients with HCV genotype 1b infection
-
[PMID: 24818763]
-
Andreone P, Colombo MG, Enejosa JV, Koksal I, Ferenci P, Maieron A, Müllhaupt B, Horsmans Y, Weiland O, Reesink HW, Rodrigues L, Hu YB, Podsadecki T, Bernstein B. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatmentexperienced patients with HCV genotype 1b infection. Gastroenterology 2014;147: 359-365.e1 [PMID: 24818763 DOI: 10.1053/j.gastro.2014.04.045]
-
(2014)
Gastroenterology
, vol.147
, pp. 359-365.e1
-
-
Andreone, P.1
Colombo, M.G.2
Enejosa, J.V.3
Koksal, I.4
Ferenci, P.5
Maieron, A.6
Müllhaupt, B.7
Horsmans, Y.8
Weiland, O.9
Reesink, H.W.10
Rodrigues, L.11
Hu, Y.B.12
Podsadecki, T.13
Bernstein, B.14
-
134
-
-
34248365628
-
Identification of determinants involved in initiation of hepatitis C virus RNA synthesis by using intergenotypic replicase chimeras
-
[PMID: 17344294]
-
Binder M, Quinkert D, Bochkarova O, Klein R, Kezmic N, Bartenschlager R, Lohmann V. Identification of determinants involved in initiation of hepatitis C virus RNA synthesis by using intergenotypic replicase chimeras. J Virol 2007; 81: 5270-5283 [PMID: 17344294 DOI: 10.1128/JVI.00032-07]
-
(2007)
J Virol
, vol.81
, pp. 5270-5283
-
-
Binder, M.1
Quinkert, D.2
Bochkarova, O.3
Klein, R.4
Kezmic, N.5
Bartenschlager, R.6
Lohmann, V.7
-
135
-
-
79960406328
-
NS4B self-interaction through conserved C-terminal elements is required for the establishment of functional hepatitis C virus replication complexes
-
[PMID: 21543474]
-
Paul D, Romero-Brey I, Gouttenoire J, Stoitsova S, Krijnse-Locker J, Moradpour D, Bartenschlager R. NS4B self-interaction through conserved C-terminal elements is required for the establishment of functional hepatitis C virus replication complexes. J Virol 2011; 85: 6963-6976 [PMID: 21543474 DOI: 10.1128/JVI.00502-11]
-
(2011)
J Virol
, vol.85
, pp. 6963-6976
-
-
Paul, D.1
Romero-Brey, I.2
Gouttenoire, J.3
Stoitsova, S.4
Krijnse-Locker, J.5
Moradpour, D.6
Bartenschlager, R.7
-
136
-
-
66149129922
-
The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients
-
[PMID: 19353740]
-
Flisiak R, Feinman SV, Jablkowski M, Horban A, Kryczka W, Pawlowska M, Heathcote JE, Mazzella G, Vandelli C, Nicolas-Métral V, Grosgurin P, Liz JS, Scalfaro P, Porchet H, Crabbé R. The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients. Hepatology 2009; 49: 1460-1468 [PMID: 19353740 DOI: 10.1002/hep]
-
(2009)
Hepatology
, vol.49
, pp. 1460-1468
-
-
Flisiak, R.1
Feinman, S.V.2
Jablkowski, M.3
Horban, A.4
Kryczka, W.5
Pawlowska, M.6
Heathcote, J.E.7
Mazzella, G.8
Vandelli, C.9
Nicolas-Métral, V.10
Grosgurin, P.11
Liz, J.S.12
Scalfaro, P.13
Porchet, H.14
Crabbé, R.15
-
137
-
-
84940788102
-
Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II)
-
[PMID: 26238707]
-
Zeuzem S, Flisiak R, Vierling JM, Mazur W, Mazzella G, Thongsawat S, Abdurakhmanov D, Van Kính N, Calistru P, Heo J, Stanciu C, Gould M, Makara M, Hsu SJ, Buggisch P, Samuel D, Mutimer D, Nault B, Merz M, Bao W, Griffel LH, Brass C, Naoumov NV. Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II). Aliment Pharmacol Ther 2015; 42: 829-844 [PMID: 26238707 DOI: 10.1111/apt.13342]
-
(2015)
Aliment Pharmacol Ther
, vol.42
, pp. 829-844
-
-
Zeuzem, S.1
Flisiak, R.2
Vierling, J.M.3
Mazur, W.4
Mazzella, G.5
Thongsawat, S.6
Abdurakhmanov, D.7
Van Kính, N.8
Calistru, P.9
Heo, J.10
Stanciu, C.11
Gould, M.12
Makara, M.13
Hsu, S.J.14
Buggisch, P.15
Samuel, D.16
Mutimer, D.17
Nault, B.18
Merz, M.19
Bao, W.20
Griffel, L.H.21
Brass, C.22
Naoumov, N.V.23
more..
-
138
-
-
84892529894
-
EASL Clinical Practice Guidelines: management of hepatitis C virus infection
-
[PMID: 24331294]
-
European Association for Study of Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2014; 60: 392-420 [PMID: 24331294 DOI: 10.1016/j.jhep.2013.11.003]
-
(2014)
J Hepatol
, vol.60
, pp. 392-420
-
-
-
139
-
-
84954423258
-
-
AISF Guidelines e Position Papers
-
AISF Guidelines e Position Papers. 2015. Available from: URL: http://www.webaisf.org/pubblicazioni/guidelines-e-positionpapers. aspx
-
(2015)
-
-
-
140
-
-
84977629626
-
Hepatitis C virus infection treatment: An era of game changer direct acting antivirals and novel treatment strategies
-
[PMID: 25373616]
-
Shahid I, ALMalki WH, Hafeez MH, Hassan S. Hepatitis C virus infection treatment: An era of game changer direct acting antivirals and novel treatment strategies. Crit Rev Microbiol 2014: 1-13 [PMID: 25373616 DOI: 10.3109/1040841X.2014.970123]
-
(2014)
Crit Rev Microbiol
, pp. 1-13
-
-
Shahid, I.1
AlMalki, W.H.2
Hafeez, M.H.3
Hassan, S.4
-
141
-
-
84919628488
-
Current and future HCV therapy: do we still need other anti-HCV drugs?
-
[PMID: 25529081]
-
Petta S, Craxì A. Current and future HCV therapy: do we still need other anti-HCV drugs? Liver Int 2015; 35 Suppl 1: 4-10 [PMID: 25529081 DOI: 10.1111/liv.12714]
-
(2015)
Liver Int
, vol.35
, pp. 4-10
-
-
Petta, S.1
Craxì, A.2
|